aldehydo-glucose - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	aldehydo-glucose	go back to main search page
Accession:	CHEBI:37663	browse the term
Definition:	The open chain form of glucose.
Synonyms:	exact_synonym:	aldehydo-gluco-hexose
	related_synonym:	Formula=C6H12O6; rel-(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

show annotations for term's descendants Sort by:
Rat (1682) Mouse (1867) Human (1734) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (10) Green Monkey (0) Naked Mole-rat (0) All
Genes (1682)

3-O-methyl-D-glucose

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

insulin 1

multiple interactions
increases uptake
increases transport

Manganese deficiency inhibits the reaction [INS1 protein results in increased uptake of 3-O-Methylglucose]; oxophenylarsine inhibits the reaction [INS1 protein results in increased transport of 3-O-Methylglucose]; pervanadate promotes the reaction [INS1 protein results in increased uptake of 3-O-Methylglucose]; Quercetin inhibits the reaction [pervanadate promotes the reaction [INS1 protein results in increased uptake of 3-O-Methylglucose]]

PMID:2185640 PMID:2204694 PMID:8404595

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

solute carrier family 2 member 1

multiple interactions
increases uptake
decreases transport

Pentobarbital inhibits the reaction [SLC2A1 protein results in increased uptake of 3-O-Methylglucose]; Pentobarbital promotes the reaction [SLC2A1 gene polymorphism results in decreased uptake of 3-O-Methylglucose]; Phenobarbital inhibits the reaction [SLC2A1 protein results in increased uptake of 3-O-Methylglucose]; Phenobarbital promotes the reaction [SLC2A1 gene polymorphism results in decreased uptake of 3-O-Methylglucose]
SLC2A1 protein mutant form results in decreased transport of 3-O-Methylglucose

PMID:10590023 PMID:11603379

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

solute carrier family 2 member 2

multiple interactions
increases uptake

Fluorouracil promotes the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose]; Phloretin inhibits the reaction [Fluorouracil promotes the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose]]; Phloretin inhibits the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose]
Cytochalasin B inhibits the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose]; Mercuric Chloride inhibits the reaction [SLC2A2 protein results in increased uptake of 3-O-Methylglucose]

PMID:10825458 PMID:15986457

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

aldehydo-D-glucosamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetoacetyl-CoA synthetase

increases expression

Glucosamine results in increased expression of AACS mRNA

NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954

G

ATP binding cassette subfamily G member 1

increases expression

Glucosamine results in increased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

acetyl-CoA carboxylase alpha

increases expression

Glucosamine results in increased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

aggrecan

multiple interactions
increases expression
decreases expression
affects expression

Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine results in decreased cleavage of and results in decreased secretion of ACAN protein
Glucosamine results in increased expression of ACAN mRNA
Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA]
Glucosamine analog results in increased expression of ACAN protein; Glucosamine results in increased expression of ACAN mRNA; Glucosamine results in increased expression of ACAN protein
Glucosamine analog results in decreased expression of ACAN mRNA
Glucosamine analog affects the expression of ACAN mRNA

PMID:12801482 PMID:16300972 PMID:16872674 PMID:17109745 PMID:17337215 More...

NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627

G

acyl-CoA thioesterase 1

increases expression

Glucosamine results in increased expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA oxidase 2

decreases expression

Glucosamine results in decreased expression of ACOX2 mRNA

NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160

G

acyl-CoA synthetase short-chain family member 2

increases expression

Glucosamine results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

ADAM metallopeptidase domain 15

multiple interactions
decreases expression

Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA]

NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113

G

ADAM metallopeptidase domain 17

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

decreases expression
multiple interactions

Glucosamine analog results in decreased expression of ADAMTS1 mRNA
Glucosamine results in decreased expression of ADAMTS1 mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA]

PMID:16300972 PMID:17109745

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

ADAM metallopeptidase with thrombospondin type 1 motif, 20

decreases cleavage

Glucosamine results in decreased cleavage of ADAMTS20 protein alternative form

NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

increases expression

Glucosamine results in increased expression of ADAMTS4 mRNA

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

decreases expression
multiple interactions

Glucosamine analog results in decreased expression of ADAMTS5 mRNA
Glucosamine results in decreased cleavage of and results in decreased activity of ADAMTS5 protein alternative form

PMID:16300972 PMID:19909832

NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205

G

ADAM metallopeptidase with thrombospondin type 1 motif, 9

decreases cleavage

Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form

NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929

G

adiponectin, C1Q and collagen domain containing

increases expression

Glucosamine results in increased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

alpha-fetoprotein

increases expression

Glucosamine results in increased expression of AFP mRNA

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

angiotensinogen

increases expression

Glucosamine results in increased expression of AGT mRNA

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

Abelson helper integration site 1

decreases expression

Glucosamine results in decreased expression of AHI1 mRNA

NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041

G

AKT serine/threonine kinase 1

affects phosphorylation
multiple interactions

Glucosamine analog affects the phosphorylation of AKT1 protein
Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]
Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein]

PMID:18080321 PMID:18340449 PMID:30602124

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions

[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

ALG12, alpha-1,6-mannosyltransferase

decreases expression

Glucosamine results in decreased expression of ALG12 mRNA

NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458

G

alkaline phosphatase, biomineralization associated

multiple interactions
increases expression
increases activity

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased activity of ALPL protein]
Glucosamine analog results in increased expression of ALPL mRNA

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

apolipoprotein A1

increases secretion
increases stability

Glucosamine results in increased secretion of APOA1 protein
Glucosamine results in increased stability of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein B

multiple interactions
increases degradation
increases ubiquitination
decreases secretion
decreases localization
decreases expression

acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; Glucosamine results in decreased expression of and results in decreased secretion of APOB protein; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein]
Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein]
Glucosamine results in increased ubiquitination of APOB protein
Glucosamine results in decreased localization of APOB protein
Glucosamine results in decreased expression of APOB protein

PMID:15618547 PMID:19383982

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein E

multiple interactions

[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

argininosuccinate synthase 1

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA]

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

activating transcription factor 3

decreases expression

Glucosamine results in decreased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

increases expression
multiple interactions

Glucosamine results in increased expression of ATF4 mRNA; Glucosamine results in increased expression of ATF4 protein
NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]

PMID:30602124 PMID:33812996

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

multiple interactions
increases expression
decreases expression

4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]
Glucosamine results in increased expression of ATF6 protein
ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]
Glucosamine results in decreased expression of ATF6 mRNA

PMID:17178593 PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

activating transcription factor 7 interacting protein

increases expression

Glucosamine results in increased expression of ATF7IP mRNA

NCBI chr 4:169,385,872...169,471,652
Ensembl chr 4:169,385,872...169,471,650

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

decreases expression

Glucosamine results in decreased expression of ATP2A2 mRNA

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

antizyme inhibitor 1

decreases expression
multiple interactions

Glucosamine results in decreased expression of AZIN1 mRNA
IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA]

NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578

G

beta-1,3-glucuronyltransferase 3

multiple interactions
increases expression

[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA]

PMID:11229466 PMID:11801247

NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807

G

Bcl2-like 1

decreases expression
multiple interactions

Glucosamine results in decreased expression of BCL2L1 protein
pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein]

PMID:15972124 PMID:16850161

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

brain-derived neurotrophic factor

decreases expression

Glucosamine results in decreased expression of BDNF mRNA

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

bone gamma-carboxyglutamate protein

increases expression

Glucosamine analog results in increased expression of BGLAP mRNA

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

biglycan

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA]

NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461

G

basic helix-loop-helix ARNT like 1

decreases expression

Glucosamine results in decreased expression of BMAL1 mRNA; Glucosamine results in decreased expression of BMAL1 protein

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

bone morphogenetic protein 2

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA]

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 4

decreases expression
multiple interactions

Glucosamine results in decreased expression of BMP4 mRNA
Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA]

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

bone morphogenetic protein 6

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA]
Glucosamine results in decreased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

bone morphogenetic protein 7

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA]
Glucosamine results in increased expression of BMP7 mRNA

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

calreticulin

decreases expression

Glucosamine results in decreased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

carbonic anhydrase 3

decreases expression

Glucosamine results in decreased expression of CAR3 mRNA

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

caspase 3

increases cleavage
multiple interactions

Glucosamine results in increased cleavage of CASP3 protein
Glucosamine results in increased activity of and results in increased cleavage of CASP3 protein

PMID:16850161 PMID:22020377

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 4

decreases expression

Glucosamine results in decreased expression of CASP4 mRNA

NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092

G

carbonyl reductase 2

increases expression

Glucosamine results in increased expression of CBR2 mRNA

NCBI chr10:106,008,535...106,012,838
Ensembl chr10:105,991,589...106,013,001

G

carbonyl reductase 3

increases expression

Glucosamine results in increased expression of CBR3 mRNA

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein]
Glucosamine results in increased expression of CCL2 mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA]

PMID:17109745 PMID:18080321 PMID:18949387 PMID:19020780

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA]

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 22

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA]

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 3

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

multiple interactions

Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein]
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA]

PMID:17109745 PMID:18080321

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 7

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA]

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

cellular communication network factor 2

increases expression

Glucosamine analog results in increased expression of CCN2 mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin B1

decreases expression

Glucosamine results in decreased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

CD24 molecule

increases expression

Glucosamine results in increased expression of CD24A mRNA

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

G

Cd28 molecule

increases expression

Glucosamine results in increased expression of CD28 mRNA

NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685

G

cell division cycle 20

decreases expression

Glucosamine results in decreased expression of CDC20 mRNA

NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512

G

cell division cycle 23

decreases expression

Glucosamine results in decreased expression of CDC23 mRNA

NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163

G

cyclin-dependent kinase 1

decreases expression

Glucosamine results in decreased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase inhibitor 1A

increases expression

Glucosamine results in increased expression of CDKN1A protein
Glucosamine results in increased expression of CDKN1A mRNA

PMID:15654767 PMID:17178593

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

decreases expression

Glucosamine results in decreased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 3

decreases expression

Glucosamine results in decreased expression of CDKN3 mRNA

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

centromere protein F

decreases expression

Glucosamine results in decreased expression of CENPF mRNA

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

chitinase 3 like 1

decreases expression

Glucosamine analog results in decreased expression of CHI3L1 mRNA

NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions
decreases activity

Glucosamine analog results in decreased activity of and results in decreased localization of CHUK protein
Glucosamine analog results in decreased activity of CHUK protein

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

cytoskeleton associated protein 2

decreases expression

Glucosamine results in decreased expression of CKAP2 mRNA

NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913

G

clock circadian regulator

decreases expression

Glucosamine results in decreased expression of CLOCK mRNA; Glucosamine results in decreased expression of CLOCK protein

NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400

G

clathrin, light chain A

decreases expression

Glucosamine results in decreased expression of CLTA mRNA

NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472

G

collagen type XI alpha 1 chain

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA]

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

collagen type I alpha 1 chain

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA]
Glucosamine results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions
affects expression
increases expression

Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA]
Glucosamine analog affects the expression of COL2A1 mRNA
Glucosamine analog results in increased expression of COL2A1 mRNA; Glucosamine results in increased expression of COL2A1 mRNA

PMID:16300972 PMID:17109745 PMID:17337215 PMID:18321735

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

collagen type III alpha 1 chain

multiple interactions

Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type VIII alpha 1 chain

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA]

NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424

G

colony stimulating factor 1

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA]

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

colony stimulating factor 2

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA]
Glucosamine results in increased expression of CSF2 mRNA

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 3

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA]
Glucosamine results in increased expression of CSF3 mRNA

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

cathepsin D

affects localization
multiple interactions
increases activity
decreases expression

Glucosamine affects the localization of CTSD protein
pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form]
Glucosamine results in increased activity of CTSD protein

PMID:15972124 PMID:16850161

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cullin 2

multiple interactions

Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA]

NCBI chr17:54,169,093...54,210,197
Ensembl chr17:54,169,086...54,209,968

G

C-X-C motif chemokine ligand 1

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA]

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 10

multiple interactions

Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA]

PMID:17109745 PMID:20737476

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA]

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

C-X-C motif chemokine ligand 12

multiple interactions
decreases expression

Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA]

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA]

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine ligand 6

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA]

NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093

G

cytochrome b-245 alpha chain

decreases expression

Glucosamine results in decreased expression of CYBA mRNA

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome c, somatic

affects localization

Glucosamine affects the localization of CYCS protein

PMID:15972124 PMID:22020377

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 51

increases expression

Glucosamine results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

diazepam binding inhibitor

increases expression

Glucosamine results in increased expression of DBI mRNA

NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693

G

DNA-damage inducible transcript 3

increases expression
multiple interactions
decreases expression

Glucosamine results in increased expression of DDIT3 mRNA; Glucosamine results in increased expression of DDIT3 protein
NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 protein]
Glucosamine results in decreased expression of DDIT3 mRNA

PMID:16380481 PMID:17178593 PMID:30602124 PMID:33812996

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DNA-damage-inducible transcript 4-like

increases expression

Glucosamine results in increased expression of DDIT4L mRNA

NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375

G

7-dehydrocholesterol reductase

increases expression

Glucosamine results in increased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

DnaJ heat shock protein family (Hsp40) member B11

decreases expression

Glucosamine results in decreased expression of DNAJB11 mRNA

NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407

G

DnaJ heat shock protein family (Hsp40) member B9

decreases expression

Glucosamine results in decreased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C3

decreases expression

Glucosamine results in decreased expression of DNAJC3 mRNA

NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181

G

dentin sialophosphoprotein

decreases expression

Glucosamine analog results in decreased expression of DSPP mRNA

NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672

G

dual specificity phosphatase 5

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA]
Glucosamine results in increased expression of DUSP5 mRNA

NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818

G

dual specificity phosphatase 7

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA]

NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404

G

dynein cytoplasmic 1 intermediate chain 1

decreases expression

Glucosamine results in decreased expression of DYNC1I1 mRNA

NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149

G

ER degradation enhancing alpha-mannosidase like protein 1

decreases expression

Glucosamine results in decreased expression of EDEM1 mRNA

NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions
increases expression
increases phosphorylation

EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]
Glucosamine results in increased expression of EIF2AK3 protein
NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein]
EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]
Glucosamine results in increased phosphorylation of EIF2AK3 protein

PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
multiple interactions

Glucosamine results in increased phosphorylation of EIF2S1 protein
NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]
EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]

PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

ELOVL fatty acid elongase 6

increases expression

Glucosamine results in increased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

endothelial PAS domain protein 1

decreases expression
multiple interactions

Glucosamine results in decreased expression of EPAS1 mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA]

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

glutamyl-prolyl-tRNA synthetase 1

decreases expression

Glucosamine results in decreased expression of EPRS1 mRNA

NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions
increases expression

ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA]
Glucosamine results in increased expression of ERN1 mRNA
NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA]

PMID:30602124 PMID:33812996

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

fatty acid binding protein 4

increases expression

Glucosamine results in increased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

fatty acid synthase

increases expression

Glucosamine results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fructose-bisphosphatase 2

increases expression

Glucosamine results in increased expression of FBP2 mRNA

NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698

G

fibroblast growth factor 2

multiple interactions

Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA]

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor 7

decreases expression
multiple interactions

Glucosamine results in decreased expression of FGF7 mRNA
IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA]

NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929

G

fibroblast growth factor 9

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA]
Glucosamine results in increased expression of FGF9 mRNA

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

Fibroblast growth factor receptor 1

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA]
Glucosamine results in increased expression of FGFR1 mRNA

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

FKBP prolyl isomerase 11

decreases expression

Glucosamine results in decreased expression of FKBP11 mRNA

NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303

G

fibronectin 1

decreases expression

Glucosamine results in decreased expression of FN1 protein

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA]
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOS protein]

PMID:19375915 PMID:21825963

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

furin (paired basic amino acid cleaving enzyme)

decreases cleavage
multiple interactions

Glucosamine results in decreased cleavage of FURIN protein alternative form
Glucosamine results in decreased glycosylation of and results in decreased activity of FURIN protein

NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314

G

FXYD domain-containing ion transport regulator 2

increases expression

Glucosamine results in increased expression of FXYD2 mRNA

NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203

G

glycine amidinotransferase

decreases expression

Glucosamine results in decreased expression of GATM mRNA

NCBI chr 3:109,658,919...109,675,508
Ensembl chr 3:109,658,951...109,684,129

G

glucokinase

decreases expression

Glucosamine results in decreased expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

glutamate-cysteine ligase, catalytic subunit

increases expression

Glucosamine analog results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamine fructose-6-phosphate transaminase 1

multiple interactions

[Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein

NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471

G

glutaredoxin

increases expression

Glucosamine results in increased expression of GLRX mRNA

NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680

G

glucosamine-phosphate N-acetyltransferase 1

decreases expression

Glucosamine results in decreased expression of GNPNAT1 mRNA

NCBI chr15:18,596,180...18,608,854
Ensembl chr15:18,596,442...18,608,739

G

N-acetylglucosamine-1-phosphate transferase subunits alpha and beta

increases expression

Glucosamine results in increased expression of GNPTAB mRNA

NCBI chr 7:22,800,502...22,866,336
Ensembl chr 7:22,800,485...22,866,933

G

glycerol-3-phosphate dehydrogenase 1 like

increases expression

Glucosamine results in increased expression of GPD1L mRNA

NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723

G

gremlin 1, DAN family BMP antagonist

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA]

NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082

G

glycogen synthase kinase 3 beta

decreases phosphorylation
multiple interactions

Glucosamine results in decreased phosphorylation of GSK3B protein
Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

G1 to S phase transition 1

multiple interactions

Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]

NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198

G

glutathione S-transferase theta 1

increases expression

Glucosamine results in increased expression of GSTT1 mRNA

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

hyaluronan and proteoglycan link protein 1

decreases expression
multiple interactions

Glucosamine results in decreased expression of HAPLN1 mRNA
Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA]

NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777

G

homocysteine inducible ER protein with ubiquitin like domain 1

decreases expression

Glucosamine results in decreased expression of HERPUD1 mRNA

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
decreases expression

Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]
Glucosamine results in decreased expression of HIF1A mRNA; Glucosamine results in decreased expression of HIF1A protein

PMID:19254699 PMID:22020377

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

hexokinase 1

increases expression

Glucosamine results in increased expression of HK1 mRNA

PMID:11893929 PMID:17178593

NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131

G

high mobility group AT-hook 1

increases expression

Glucosamine results in increased expression of HMGA1 mRNA

NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

increases expression

Glucosamine results in increased expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

hyaluronan-mediated motility receptor

decreases expression

Glucosamine results in decreased expression of HMMR mRNA

NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060

G

heme oxygenase 1

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein]
Glucosamine results in increased expression of HMOX1 mRNA; Glucosamine results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homeobox A1

decreases expression

Glucosamine results in decreased expression of HOXA1 mRNA

NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504

G

15-hydroxyprostaglandin dehydrogenase

decreases expression

Glucosamine results in decreased expression of HPGD mRNA

NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228

G

heat shock protein 90 beta family member 1

decreases expression
increases expression

Glucosamine results in decreased expression of HSP90B1 mRNA
Glucosamine results in increased expression of HSP90B1 protein

PMID:15618547 PMID:17109745 PMID:17178593

NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression
decreases expression

4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]
Glucosamine results in increased expression of HSPA5 mRNA; Glucosamine results in increased expression of HSPA5 protein
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]
Glucosamine results in decreased expression of HSPA5 mRNA

PMID:15618547 PMID:16380481 PMID:17178593 PMID:19383982 PMID:20165829 More...

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

hypoxia up-regulated 1

decreases expression

Glucosamine results in decreased expression of HYOU1 mRNA

NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186

G

intercellular adhesion molecule 1

multiple interactions
decreases activity

Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein]
Glucosamine results in decreased activity of ICAM1 protein
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]

PMID:16431966 PMID:16822504 PMID:17238806 PMID:18949387 PMID:19020780 More...

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 1

increases expression

Glucosamine results in increased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

inhibitor of DNA binding 2

increases expression

Glucosamine results in increased expression of ID2 mRNA

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

inhibitor of DNA binding 3

increases expression

Glucosamine results in increased expression of ID3 mRNA

NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349

G

isocitrate dehydrogenase (NADP(+)) 1

increases expression

Glucosamine results in increased expression of IDH1 mRNA

NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708

G

interferon-induced protein with tetratricopeptide repeats 3

increases expression

Glucosamine results in increased expression of IFIT3 mRNA

NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307

G

interferon gamma

decreases secretion
multiple interactions

Glucosamine results in decreased secretion of IFNG protein
Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]

PMID:14507305 PMID:16431966 PMID:16822504 PMID:17238806

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor binding protein 3

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA]
Glucosamine results in decreased expression of IGFBP3 mRNA

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

insulin-like growth factor binding protein 4

decreases expression

Glucosamine results in decreased expression of IGFBP4 mRNA

NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225

G

insulin-like growth factor binding protein 5

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA]
Glucosamine results in increased expression of IGFBP5 mRNA

NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of IKBKB protein]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

inhibitor of nuclear factor kappa B kinase regulatory subunit gamma

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA]

NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499

G

interleukin 11

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA]

NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129

G

interleukin 13 receptor subunit alpha 1

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA]
Glucosamine results in decreased expression of IL13RA1 mRNA

NCBI chr X:115,348,822...115,408,682
Ensembl chr X:115,348,860...115,408,681
Ensembl chr11:115,348,860...115,408,681

G

interleukin 1 alpha

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
increases expression
decreases expression

[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites]; Glucosamine analog affects the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine analog inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitrites]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine promotes the reaction [IL1B results in increased expression of PPARG]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
Glucosamine results in increased expression of IL1B mRNA
Glucosamine results in decreased expression of IL1B mRNA
[IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA; Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA]
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]

PMID:11229466 PMID:11801247 PMID:12681956 PMID:15144122 PMID:16822504 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 2

multiple interactions

[IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA

NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725

G

interleukin 2

decreases secretion

Glucosamine results in decreased secretion of IL2 protein

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 23 receptor

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA]

NCBI chr 4:96,580,568...96,672,540
Ensembl chr 4:96,580,714...96,674,021

G

interleukin 33

decreases expression

Glucosamine results in decreased expression of IL33 mRNA

NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373

G

interleukin 4

decreases secretion
decreases expression

Glucosamine results in decreased secretion of IL4 protein
Glucosamine results in decreased expression of IL4

PMID:14507305 PMID:21284687

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

decreases secretion
decreases expression

Glucosamine results in decreased secretion of IL5 protein
Glucosamine results in decreased expression of IL5

PMID:14507305 PMID:21284687

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions
decreases expression

Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]
Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
Glucosamine analog results in decreased expression of IL6 mRNA; Glucosamine results in decreased expression of IL6 mRNA
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]

PMID:16822504 PMID:17109745 PMID:18786831 PMID:19098112 PMID:20093129 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inositol polyphosphate-5-phosphatase K

increases expression
multiple interactions

Glucosamine results in increased expression of INPP5K mRNA
NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA]

NCBI chr10:60,474,262...60,495,813
Ensembl chr10:60,475,897...60,496,773

G

insulin 1

multiple interactions

4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]; [Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein; Glucosamine inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]
[INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]

PMID:9453242 PMID:11893929 PMID:16380481 PMID:20165829 PMID:30602124

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]; Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]

PMID:20165829 PMID:33812996

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

interferon regulatory factor 1

multiple interactions

Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IRF1 mRNA]

NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166

G

inositol-3-phosphate synthase 1

increases expression

Glucosamine results in increased expression of ISYNA1 mRNA

NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979

G

Janus kinase 2

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA]
[Glucosamine co-treated with Lipopolysaccharides] results in increased phosphorylation of JAK2 protein

PMID:17109745 PMID:38437956

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein]
Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA]

PMID:17925024 PMID:21825963

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA]

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

JunD proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein]

NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799

G

potassium inwardly-rectifying channel, subfamily J, member 16

increases expression

Glucosamine results in increased expression of KCNJ16 mRNA

NCBI chr10:95,990,009...96,021,356
Ensembl chr10:95,960,725...96,021,702

G

kinesin family member 11

decreases expression

Glucosamine results in decreased expression of KIF11 mRNA

NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766

G

kinesin family member 4A

decreases expression

Glucosamine results in decreased expression of KIF4A mRNA

NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139

G

KLF transcription factor 10

increases expression

Glucosamine results in increased expression of KLF10 mRNA

NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994

G

laminin subunit alpha 4

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA]

NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347

G

laminin subunit beta 1

multiple interactions

TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA]

NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585

G

laminin subunit gamma 1

multiple interactions

TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA]

NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492

G

lipocalin 2

decreases expression

Glucosamine results in decreased expression of LCN2 mRNA

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

leptin receptor

multiple interactions
affects response to substance

[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

lipin 1

increases expression

Glucosamine results in increased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

lymphocyte antigen 6 family member A

increases expression

Glucosamine results in increased expression of LY6A mRNA

NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981

G

MAF bZIP transcription factor B

increases expression

Glucosamine results in increased expression of MAFB mRNA

NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]
Glucosamine analog results in increased phosphorylation of MAPK1 protein

PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein]

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]
Glucosamine analog results in increased phosphorylation of MAPK3 protein

PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions
increases phosphorylation

Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]
Glucosamine analog results in increased phosphorylation of MAPK8 protein

PMID:18080321 PMID:19626664 PMID:20307528

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

Glucosamine results in decreased expression of MCL1 mRNA; Glucosamine results in decreased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

myocyte enhancer factor 2a

multiple interactions
decreases expression

4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]
Glucosamine results in decreased expression of MEF2A mRNA; Glucosamine results in decreased expression of MEF2A protein

NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948

G

methyltransferase 1, tRNA methylguanosine

decreases expression

Glucosamine results in decreased expression of METTL1 mRNA

NCBI chr 7:62,864,860...62,869,202
Ensembl chr 7:62,864,853...62,869,202

G

microfibril associated protein 3 like

increases expression

Glucosamine results in increased expression of MFAP3L mRNA

NCBI chr16:29,411,643...29,454,665
Ensembl chr16:29,415,849...29,430,863

G

marker of proliferation Ki-67

decreases expression

Glucosamine results in decreased expression of MKI67 mRNA

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 1

multiple interactions

Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]

PMID:15144122 PMID:17925024 PMID:18080321

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 10

increases expression
multiple interactions

Glucosamine results in increased expression of MMP10 mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA]

NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748

G

matrix metallopeptidase 12

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA]

NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611

G

matrix metallopeptidase 13

affects expression
multiple interactions
increases expression

Glucosamine analog affects the expression of MMP13 mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA]
Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]

PMID:15144122 PMID:17109745 PMID:17337215 PMID:17925024 PMID:18080321 More...

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 2

multiple interactions
increases expression

Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP2 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 protein]
IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA]

PMID:17109745 PMID:17498959 PMID:19375915

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

multiple interactions
increases expression
decreases expression

[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine results in decreased expression of and results in decreased activity of MMP3 protein
Glucosamine results in increased expression of MMP3 mRNA
Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA]
Glucosamine analog results in decreased expression of MMP3 mRNA

PMID:11229466 PMID:12801482 PMID:15144122 PMID:16300972 PMID:17109745 More...

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

multiple interactions
increases expression

Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]
Glucosamine results in increased expression of MMP9 mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA]

PMID:17109745 PMID:17498959 PMID:19375915

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloid cell nuclear differentiation antigen

increases expression

Glucosamine results in increased expression of IFI204 mRNA

NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201

G

myeloperoxidase

decreases activity

Glucosamine results in decreased activity of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mevalonate diphosphate decarboxylase

increases expression

Glucosamine results in increased expression of MVD mRNA

NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971

G

Ndufa4, mitochondrial complex associated

increases expression

Glucosamine results in increased expression of NDUFA4 mRNA

NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920

G

NEDD4 E3 ubiquitin protein ligase

decreases expression

Glucosamine results in decreased expression of NEDD4 mRNA

NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951

G

nuclear factor kappa B subunit 1

multiple interactions
decreases activity

Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NFKB1 protein]
Glucosamine results in decreased activity of NFKB1 protein
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKB1 protein]

PMID:12681956 PMID:16431966 PMID:16822504 PMID:17498959 PMID:18036590 More...

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions
decreases phosphorylation
decreases expression

Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]
Glucosamine results in decreased phosphorylation of NFKBIA protein
Glucosamine results in decreased expression of NFKBIA mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA]
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA protein modified form]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]

PMID:12681956 PMID:17109745 PMID:18080321 PMID:18205790 PMID:19098112

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NFKB inhibitor beta

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA]

NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862

G

neuronal guanine nucleotide exchange factor

increases expression

Glucosamine results in increased expression of NGEF mRNA

NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914

G

nerve growth factor

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 2

multiple interactions
increases expression
decreases expression

[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]
Glucosamine results in increased expression of NOS2 mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA]
Glucosamine results in decreased expression of NOS2 mRNA
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

PMID:17109745 PMID:17440993 PMID:17605605 PMID:18077487 PMID:18205790 More...

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nuclear receptor subfamily 1, group H, member 4

affects expression

Glucosamine affects the expression of NR1H4

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

NAD(P) dependent steroid dehydrogenase-like

increases expression

Glucosamine results in increased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

nucleobindin 2

decreases expression

Glucosamine results in decreased expression of NUCB2 mRNA

NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353

G

NUF2 component of NDC80 kinetochore complex

decreases expression

Glucosamine results in decreased expression of NUF2 mRNA

NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766

G

NUS1 dehydrodolichyl diphosphate synthase subunit

multiple interactions

NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]

NCBI chr20:31,811,817...31,838,562
Ensembl chr20:31,811,817...31,838,561

G

ornithine aminotransferase

multiple interactions

Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA]

NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682

G

O-linked N-acetylglucosamine (GlcNAc) transferase

decreases expression

Glucosamine results in decreased expression of OGT mRNA

NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146

G

origin recognition complex, subunit 2

decreases expression

Glucosamine results in decreased expression of ORC2 mRNA

NCBI chr 9:60,001,631...60,038,301
Ensembl chr 9:60,001,910...60,038,195

G

oncostatin M

multiple interactions

Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA]

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

osteocrin

multiple interactions
increases expression

4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]

NCBI chr11:73,442,167...73,478,498
Ensembl chr11:73,442,487...73,468,603

G

oxidation resistance 1

decreases expression

Glucosamine results in decreased expression of OXR1 mRNA

NCBI chr 7:72,528,750...72,965,666
Ensembl chr 7:72,528,786...72,965,666

G

pantothenate kinase 1

increases expression

Glucosamine results in increased expression of PANK1 mRNA

NCBI chr 1:232,324,718...232,395,445
Ensembl chr 1:232,328,430...232,396,829

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

Glucosamine results in increased cleavage of PARP1 protein
pepstatin inhibits the reaction [Glucosamine results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

platelet derived growth factor subunit A

affects expression
multiple interactions

Glucosamine affects the expression of PDGFA mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA]

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

protein disulfide isomerase family A, member 4

decreases expression

Glucosamine results in decreased expression of PDIA4 mRNA

NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107

G

protein disulfide isomerase family A, member 6

decreases expression

Glucosamine results in decreased expression of PDIA6 mRNA

NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613

G

pyruvate dehydrogenase kinase 4

increases expression

Glucosamine results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

phosphofructokinase, platelet

increases expression

Glucosamine results in increased expression of PFKP mRNA

NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018

G

phosphatidylinositol glycan anchor biosynthesis, class A

decreases expression

Glucosamine results in decreased expression of PIGA mRNA

NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804

G

phospholipase A2 group IIA

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]

NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014

G

phospholipase A2 group 4A

affects expression
multiple interactions

Glucosamine affects the expression of PLA2G4A mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA]

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

phospholipase A2, group V

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA]

NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658

G

plasminogen activator, tissue type

increases expression

Glucosamine results in increased expression of PLAT mRNA

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

polo-like kinase 1

increases expression
decreases expression

Glucosamine results in increased expression of PLK1 mRNA
Glucosamine results in decreased expression of PLK1 mRNA

PMID:17109745 PMID:17178593

NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400

G

phospholipid phosphatase 3

decreases expression

Glucosamine results in decreased expression of PLPP3 mRNA

NCBI chr 5:119,927,085...120,002,206
Ensembl chr 5:119,927,085...120,002,205

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

Glucosamine promotes the reaction [IL1B results in increased expression of PPARG]
Glucosamine results in increased expression of PPARG mRNA

PMID:15694357 PMID:22089456

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions
decreases expression

4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]
Glucosamine results in decreased expression of PPARGC1A mRNA; Glucosamine results in decreased expression of PPARGC1A protein

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase, Mg2+/Mn2+ dependent, 1A

decreases expression

Glucosamine results in decreased expression of PPM1A mRNA

NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697

G

protein phosphatase 1, regulatory subunit 15A

decreases expression

Glucosamine results in decreased expression of PPP1R15A mRNA

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

protein regulator of cytokinesis 1

decreases expression

Glucosamine results in decreased expression of PRC1 mRNA

NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

proteasome activator subunit 3

decreases expression

Glucosamine results in decreased expression of PSME3

NCBI chr10:86,257,672...86,265,458
Ensembl chr10:86,257,668...86,333,804

G

prostaglandin E synthase

multiple interactions

[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA]

PMID:17605605 PMID:22089456

NCBI chr 3:14,177,892...14,189,236

G

prostaglandin-endoperoxide synthase 2

increases expression
decreases expression
multiple interactions
decreases glycosylation

Glucosamine analog results in increased expression of PTGS2 protein alternative form
Glucosamine results in decreased expression of PTGS2 mRNA
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
Glucosamine results in decreased glycosylation of PTGS2 protein
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]

PMID:12681956 PMID:17440993 PMID:17605605 PMID:18205790 PMID:19656660 More...

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

PTTG1 regulator of sister chromatid separation, securin

decreases expression

Glucosamine results in decreased expression of PTTG1 mRNA

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

RAB32, member RAS oncogene family

increases expression

Glucosamine results in increased expression of RAB32 mRNA

NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934

G

Rac GTPase-activating protein 1

decreases expression

Glucosamine results in decreased expression of RACGAP1 mRNA

NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831

G

RNA binding motif protein 39

decreases expression

Glucosamine results in decreased expression of RBM39 mRNA

NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213

G

RecQ like helicase 4

increases expression

Glucosamine results in increased expression of RECQL4 mRNA

NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
decreases activity
increases localization

Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]
Glucosamine results in decreased activity of RELA protein
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]
Glucosamine results in increased localization of RELA protein

PMID:12681956 PMID:16431966 PMID:16822504 PMID:17238806 PMID:17498959 More...

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RELB proto-oncogene, NF-kB subunit

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA]

NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507

G

ras homolog family member B

increases expression

Glucosamine results in increased expression of RHOB mRNA

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

ras homolog family member C

decreases expression

Glucosamine analog results in decreased expression of RHOC mRNA

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

Rho family GTPase 1

multiple interactions
decreases expression

Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA]
Glucosamine results in decreased expression of RND1 mRNA

PMID:17178593 PMID:18173918

NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399

G

ribosomal protein S6

decreases phosphorylation

Glucosamine results in decreased phosphorylation of RPS6 protein

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

ribosomal protein S6 kinase B1

decreases phosphorylation

Glucosamine results in decreased phosphorylation of RPS6KB1 protein

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

RUNX family transcription factor 2

increases phosphorylation
increases expression
multiple interactions

Glucosamine analog results in increased phosphorylation of RUNX2 protein
Glucosamine analog results in increased expression of RUNX2 mRNA
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

stearoyl-Coenzyme A desaturase 2

increases expression

Glucosamine results in increased expression of SCD2 mRNA

NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232

G

syndecan 2

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA]

NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081

G

syndecan 4

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA]

NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580

G

selenium binding protein 1

decreases expression

Glucosamine results in decreased expression of SELENBP1 mRNA

NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594

G

serpin family B member 2

increases expression

Glucosamine results in increased expression of SERPINB2 mRNA

NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408

G

serpin family H member 1

increases expression

Glucosamine results in increased expression of SERPINH1 protein

NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801

G

secreted frizzled-related protein 2

decreases expression

Glucosamine results in decreased expression of SFRP2 mRNA

NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063

G

serum/glucocorticoid regulated kinase 1

decreases expression

Glucosamine results in decreased expression of SGK1 mRNA

NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283

G

SHC binding and spindle associated 1

decreases expression

Glucosamine results in decreased expression of SHCBP1 mRNA

NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844

G

solute carrier family 17 member 1

increases expression

Glucosamine results in increased expression of SLC17A1 mRNA

NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304

G

solute carrier family 23 member 2

increases expression

Glucosamine results in increased expression of SLC23A2 mRNA

NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343

G

solute carrier family 2 member 2

decreases expression

Glucosamine results in decreased expression of SLC2A2 mRNA

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

G

solute carrier family 2 member 4

multiple interactions
decreases expression
increases uptake

4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]
Glucosamine results in decreased expression of SLC2A4 mRNA; Glucosamine results in decreased expression of SLC2A4 protein
SLC2A4 protein results in increased uptake of Glucosamine
Glucosamine inhibits the reaction [SLC2A4 protein results in increased uptake of Glucose]; Glucose inhibits the reaction [SLC2A4 protein results in increased uptake of Glucosamine]

PMID:19373748 PMID:20165829

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 2 member 6

decreases expression

Glucosamine results in decreased expression of SLC2A6 mRNA

NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208

G

solute carrier family 37 member 4

increases expression

Glucosamine results in increased expression of SLC37A4 mRNA

NCBI chr 8:44,723,216...44,729,301
Ensembl chr 8:44,723,339...44,729,301

G

solute carrier family 4 member 4

decreases expression

Glucosamine results in decreased expression of SLC4A4 mRNA

NCBI chr14:18,841,289...19,293,297
Ensembl chr14:18,845,159...19,272,883

G

solute carrier family 7 member 8

increases expression
multiple interactions

Glucosamine results in increased expression of SLC7A8 mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA]

NCBI chr15:28,183,013...28,242,717
Ensembl chr15:28,183,015...28,242,717

G

SMAD family member 2

multiple interactions
increases phosphorylation

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of SMAD2 protein]

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

sphingomyelin phosphodiesterase 3

decreases expression

Glucosamine results in decreased expression of SMPD3 mRNA

NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749

G

SRY-box transcription factor 4

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA]
Glucosamine results in decreased expression of SOX4 mRNA

NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665

G

serine and arginine rich splicing factor 3

decreases expression

Glucosamine results in decreased expression of SRSF3 mRNA

NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078

G

ST6 beta-galactoside alpha-2,6-sialyltransferase 1

increases expression

Glucosamine results in increased expression of ST6GAL1 mRNA

NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310

G

signal transducer and activator of transcription 1

multiple interactions

Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein]

PMID:16431966 PMID:17238806

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

transforming, acidic coiled-coil containing protein 3

decreases expression

Glucosamine results in decreased expression of TACC3 mRNA

NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219

G

testin gene

decreases expression

Glucosamine results in decreased expression of TESTIN mRNA

NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385

G

transforming growth factor alpha

multiple interactions

[Glucose co-treated with Glucosamine] results in increased expression of TGFA protein; Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA]

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta 1

increases expression

Glucosamine analog results in increased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta receptor 1

increases expression
multiple interactions

Glucosamine analog results in increased expression of TGFBR1 protein
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased expression of TGFBR1 protein]

NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777

G

thrombospondin 4

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA]

NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313

G

TIMP metallopeptidase inhibitor 1

multiple interactions
increases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 2

affects expression
multiple interactions

Glucosamine affects the expression of TIMP2 mRNA
Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA]

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

TIMP metallopeptidase inhibitor 3

multiple interactions
increases expression

[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA
Glucosamine results in increased expression of TIMP3 mRNA
Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA]

PMID:17109745 PMID:17605605

NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839

G

tubulointerstitial nephritis antigen

increases expression

Glucosamine results in increased expression of TINAG mRNA

NCBI chr 8:77,800,031...77,885,077
Ensembl chr 8:77,800,032...77,885,077

G

thymidine kinase 1

decreases expression

Glucosamine results in decreased expression of TK1 mRNA

NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920

G

toll-like receptor 1

increases expression

Glucosamine results in increased expression of TLR1 mRNA

NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125

G

tumor necrosis factor

decreases secretion
multiple interactions
decreases expression

Glucosamine results in decreased secretion of TNF protein
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Glucosamine analog results in decreased expression of TNF mRNA; Glucosamine results in decreased expression of TNF mRNA
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF; Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]; Glucosamine promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]

PMID:14507305 PMID:16431966 PMID:16445576 PMID:16822504 PMID:17238806 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 6

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA]

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

TNF receptor superfamily member 11B

multiple interactions

[Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF receptor superfamily member 1A

multiple interactions

Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

TNF receptor superfamily member 1B

multiple interactions

Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

G

TNF superfamily member 11

multiple interactions
increases expression

[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA]

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

tyrosine kinase, non-receptor, 2

multiple interactions

Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA]

NCBI chr11:68,114,725...68,154,254
Ensembl chr11:68,114,726...68,154,009

G

DNA topoisomerase II alpha

decreases expression

Glucosamine results in decreased expression of TOP2A mRNA

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

TNF receptor associated factor 6

multiple interactions

Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]

NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507

G

transient receptor potential cation channel, subfamily V, member 4

increases expression

Glucosamine results in increased expression of TRPV4 mRNA

NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517

G

thioredoxin 1

decreases expression

Glucosamine results in decreased expression of TXN1 protein

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin interacting protein

increases expression
multiple interactions

Glucosamine results in increased expression of TXNIP protein
Glucosamine results in increased expression of TXNIP mRNA; Glucosamine results in increased expression of TXNIP protein
Glucosamine promotes the reaction [TXNIP results in increased abundance of Reactive Oxygen Species]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA]

NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886

G

uncoupling protein 2

decreases expression

Glucosamine results in decreased expression of UCP2 mRNA

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

ubiquinol-cytochrome c reductase hinge protein

increases expression

Glucosamine results in increased expression of UQCRH mRNA

NCBI chr 5:129,545,978...129,554,173
Ensembl chr 5:129,545,984...129,554,242

G

vesicle-associated membrane protein 1

increases expression

Glucosamine results in increased expression of VAMP1 mRNA

NCBI chr 4:158,012,634...158,019,350
Ensembl chr 4:158,012,663...158,019,349

G

versican

multiple interactions
decreases expression

Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA]

NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637

G

vascular endothelial growth factor A

multiple interactions
increases expression
decreases expression

Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]
Glucosamine results in increased expression of VEGFA protein
Glucosamine results in decreased expression of VEGFA protein

PMID:16324875 PMID:19254699

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor D

increases expression
decreases expression

Glucosamine results in increased expression of VEGFD mRNA
Glucosamine results in decreased expression of VEGFD mRNA

PMID:17109745 PMID:17178593

NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295

G

vanin 1

increases expression

Glucosamine results in increased expression of VNN1 mRNA

NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395

G

X-box binding protein 1

multiple interactions
increases splicing
increases expression
decreases splicing

4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]
Glucosamine results in increased expression of XBP1 protein alternative form
4-methylumbelliferone 8-carbaldehyde affects the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA]
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]
Glucosamine results in decreased splicing of XBP1 mRNA

PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

xanthine dehydrogenase

multiple interactions

[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

G

zinc finger protein 467

increases expression

Glucosamine results in increased expression of ZFP467 mRNA

NCBI chr 4:77,385,752...77,394,709
Ensembl chr 4:77,385,758...77,392,229

aldehydo-D-glucosamine 6-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

CCAAT/enhancer binding protein alpha

decreases expression

glucosamine 6-phosphate results in decreased expression of CEBPA protein

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

delta like non-canonical Notch ligand 1

decreases expression

glucosamine 6-phosphate results in decreased expression of DLK1 mRNA

NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522

G

fatty acid binding protein 4

decreases expression

glucosamine 6-phosphate results in decreased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

Fas cell surface death receptor

decreases expression

glucosamine 6-phosphate results in decreased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucosamine 6-phosphate]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

leptin

decreases expression

glucosamine 6-phosphate results in decreased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase E, hormone sensitive type

increases expression

glucosamine 6-phosphate results in increased expression of LIPE mRNA

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

lipoprotein lipase

decreases expression

glucosamine 6-phosphate results in decreased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

peroxisome proliferator-activated receptor gamma

decreases expression

glucosamine 6-phosphate results in decreased expression of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

sterol regulatory element binding transcription factor 1

decreases expression

glucosamine 6-phosphate results in decreased expression of SREBF1 protein

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

tumor necrosis factor

decreases expression

glucosamine 6-phosphate results in decreased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

aldehydo-D-glucose

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of A2M mRNA

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily A member 1

decreases expression
multiple interactions

Glucose results in decreased expression of ABCA1 mRNA; Glucose results in decreased expression of ABCA1 protein
morroniside inhibits the reaction [Glucose results in decreased expression of ABCA1 mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of ABCA1 protein]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 1A

decreases expression

Glucose results in decreased expression of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily B member 7

decreases expression

Glucose results in decreased expression of ABCB7 mRNA

NCBI chr X:69,295,598...69,436,775
Ensembl chr X:69,295,552...69,436,858

G

ATP binding cassette subfamily C member 1

multiple interactions

Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]]; Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]]

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions

[Benzbromarone results in decreased activity of ABCC2 protein] inhibits the reaction [Glucose results in increased secretion of S-(2,4-dinitrophenyl)glutathione]; [Furosemide results in increased activity of ABCC2 protein] promotes the reaction [Glucose results in increased secretion of S-(2,4-dinitrophenyl)glutathione]; [sulfanitran results in increased activity of ABCC2 protein] promotes the reaction [Glucose results in increased secretion of S-(2,4-dinitrophenyl)glutathione]

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily D member 2

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ABCD2 mRNA

NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642

G

ATP binding cassette subfamily G member 1

decreases expression
multiple interactions

Glucose results in decreased expression of ABCG1 mRNA; Glucose results in decreased expression of ABCG1 protein
morroniside inhibits the reaction [Glucose results in decreased expression of ABCG1 mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of ABCG1 protein]

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

acetyl-CoA carboxylase alpha

multiple interactions
decreases expression
increases expression
decreases phosphorylation

[INS protein co-treated with Glucose] results in increased expression of ACACA mRNA; [Pyruvic Acid co-treated with Glucose] results in increased phosphorylation of ACACA protein; PRKAA2 protein promotes the reaction [SIRT1 protein inhibits the reaction [Glucose results in decreased phosphorylation of ACACA protein]]; SIRT1 protein inhibits the reaction [Glucose results in decreased phosphorylation of ACACA protein]; SRT1720 inhibits the reaction [[INS protein co-treated with Glucose] results in increased expression of ACACA mRNA]
Glucose results in decreased expression of ACACA protein modified form
Glucose results in increased expression of ACACA mRNA

PMID:15066988 PMID:18482975 PMID:19071085 PMID:19724016 PMID:24349266 More...

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

multiple interactions
decreases phosphorylation

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [ACACB protein affects the reaction [Glucose results in decreased expression of PPARGC1A protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [ACACB protein affects the reaction [Glucose results in decreased expression of SIRT1 protein]]; ACACB protein affects the reaction [Glucose results in decreased expression of NPHS1 protein]; ACACB protein affects the reaction [Glucose results in decreased expression of PPARGC1A protein]; ACACB protein affects the reaction [Glucose results in decreased expression of SIRT1 protein]; ACACB protein affects the reaction [Glucose results in decreased expression of SLC2A4 protein]; ACACB protein affects the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; ACACB protein affects the reaction [Glucose results in decreased phosphorylation of IRS1 protein]
Glucose results in decreased phosphorylation of ACACB protein

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

acyl-CoA dehydrogenase, short/branched chain

multiple interactions

2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA]; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA; Rosiglitazone affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of ACADSB mRNA]

NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379

G

angiotensin I converting enzyme

increases expression
multiple interactions
decreases expression

Glucose results in increased expression of ACE protein
NFE2L2 protein affects the reaction [Glucose results in increased expression of ACE mRNA]; oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]
CEBPB protein inhibits the reaction [Glucose results in increased expression of ACE protein]
Glucose results in decreased expression of ACE mRNA
Enalaprilat inhibits the reaction [Glucose results in increased expression of ACE protein]

PMID:16452552 PMID:29211853 PMID:29266779 PMID:31655124

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions
decreases expression

NFE2L2 protein affects the reaction [Glucose results in decreased expression of ACE2 mRNA]; oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]
CEBPB protein inhibits the reaction [Glucose results in decreased expression of ACE2 protein]; Glucose inhibits the reaction [CEBPB protein binds to ACE2 promoter]; Valsartan inhibits the reaction [Glucose results in decreased expression of ACE2 protein]

PMID:29211853 PMID:29266779

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acetylcholinesterase

multiple interactions
decreases activity

Ascorbic Acid inhibits the reaction [Glucose results in decreased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

ATP citrate lyase

increases expression

Glucose results in increased expression of ACLY mRNA
Glucose deficiency results in increased expression of ACLY mRNA; Glucose deficiency results in increased expression of ACLY protein

PMID:24349266 PMID:26811028

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

G

aconitase 1

multiple interactions
increases expression

[Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein; Oxygen inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the activity of ACO1 protein]
Glucose results in increased expression of ACO1 protein

PMID:16135072 PMID:38483099

NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391

G

aconitase 2

multiple interactions

[Glucose co-treated with Oxygen] affects the activity of ACO2 protein; Glucose results in decreased expression of and results in decreased activity of ACO2 protein; LONP1 protein affects the reaction [SRT1720 inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of ACO2 protein]]; manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin inhibits the reaction [[Glucose co-treated with Oxygen] affects the activity of ACO2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Glucose co-treated with Oxygen] affects the activity of ACO2 protein]; SRT1720 inhibits the reaction [Glucose results in decreased expression of and results in decreased activity of ACO2 protein]

PMID:11520895 PMID:31639451

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

acyl-CoA thioesterase 1

increases expression
multiple interactions

Glucose results in increased expression of ACOT1 mRNA
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of ACOT1 mRNA

PMID:17178593 PMID:37567420

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA oxidase 1

increases expression

Glucose results in increased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA oxidase 2

decreases expression

Glucose results in decreased expression of ACOX2 mRNA

NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160

G

acyl-CoA synthetase bubblegum family member 1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of ACSBG1 mRNA

NCBI chr 8:54,991,294...55,047,276
Ensembl chr 8:54,991,296...55,047,391

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of ACSL4 protein; qishen yiqi inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of ACSL4 protein]

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

acyl-CoA synthetase medium-chain family member 2

increases expression

Glucose results in increased expression of ACSM2 mRNA

NCBI chr 1:173,916,368...173,955,116
Ensembl chr 1:173,916,368...173,955,116

G

acyl-CoA synthetase medium-chain family member 3

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ACSM3 mRNA

NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184

G

acyl-CoA synthetase short-chain family member 1

increases expression

Glucose results in increased expression of ACSS1 mRNA

NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325

G

acyl-CoA synthetase short-chain family member 2

increases expression

Glucose results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

actin, alpha 1, skeletal muscle

increases expression
decreases expression
multiple interactions

Glucose results in increased expression of ACTA1 mRNA
Glucose results in decreased expression of ACTA1 mRNA
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ACTA1 mRNA; fucoxanthin inhibits the reaction [Glucose results in decreased expression of ACTA1 mRNA]
HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of ACTA1 mRNA]]; Propofol inhibits the reaction [Glucose results in increased expression of ACTA1 mRNA]; STAT3 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased expression of ACTA1 mRNA]]

PMID:24810525 PMID:33448797 PMID:37567420

NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Glucose results in increased expression of ACTA2 protein]; [Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein]; DKK1 protein inhibits the reaction [Glucose results in increased expression of ACTA2 mRNA]; DKK1 protein inhibits the reaction [Glucose results in increased expression of ACTA2 protein]; MAPK14 protein promotes the reaction [[Glucose co-treated with TGFB1 protein] results in increased expression of ACTA2 protein]; MAPK14 protein promotes the reaction [Glucose results in increased expression of ACTA2 protein]
Glucose results in increased expression of ACTA2 mRNA; Glucose results in increased expression of ACTA2 protein
cinnamaldehyde inhibits the reaction [Glucose results in increased expression of ACTA2 protein]

PMID:20060012 PMID:21829520 PMID:26045780 PMID:29163160 PMID:35961541

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actin, beta

decreases expression

Glucose deficiency results in decreased expression of ACTB protein

NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877

G

actin, gamma 1

multiple interactions

ACTG1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]

NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232
Ensembl chr 3:105,619,737...105,624,232

G

actin related protein 2

multiple interactions
decreases expression

Eucalyptol inhibits the reaction [Glucose results in decreased expression of ACTR2 protein]

NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524

G

ADAM metallopeptidase domain 17

decreases expression

Glucose results in decreased expression of ADAM17 mRNA

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

ADAM metallopeptidase domain 19

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of ADAM19 mRNA

NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105

G

ADAM metallopeptidase domain 32

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of ADAM32 mRNA

NCBI chr16:67,102,384...67,212,163
Ensembl chr16:67,102,320...67,212,161

G

ADAM metallopeptidase domain 7

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of ADAM7 mRNA

NCBI chr15:42,833,796...42,882,201
Ensembl chr15:42,833,796...42,882,201

G

ADAM metallopeptidase domain 8

increases expression
multiple interactions

Glucose results in increased expression of ADAM8 mRNA
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADAM8 mRNA

PMID:17178593 PMID:37567420

NCBI chr 1:194,776,559...194,789,330
Ensembl chr 1:194,770,060...194,788,801

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression

Glucose results in increased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

adenylate cyclase 7

decreases methylation
multiple interactions
increases expression

Glucose results in decreased methylation of ADCY7 gene
fucoxanthin inhibits the reaction [Glucose results in decreased methylation of ADCY7 gene]; fucoxanthin inhibits the reaction [Glucose results in increased expression of ADCY7 mRNA]

NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311

G

adhesion G protein-coupled receptor A1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADGRA1 mRNA

NCBI chr 1:194,629,744...194,673,254
Ensembl chr 1:194,629,726...194,672,550

G

adhesion G protein-coupled receptor B1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADGRB1 mRNA

NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902

G

adhesion G protein-coupled receptor E4

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADGRE4 mRNA

NCBI chr 9:9,758,106...9,901,908
Ensembl chr 9:9,760,355...9,900,760

G

adhesion G protein-coupled receptor F4

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ADGRF4 mRNA

NCBI chr 9:18,272,050...18,303,219
Ensembl chr 9:18,272,050...18,303,217

G

adhesion G protein-coupled receptor G4

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of ADGRG4 mRNA

NCBI chr X:134,734,610...134,864,449
Ensembl chr X:134,854,736...134,864,449

G

alcohol dehydrogenase, iron containing, 1

decreases expression

Glucose results in decreased expression of ADHFE1 mRNA

NCBI chr 5:9,705,966...9,732,580
Ensembl chr 5:9,705,970...9,732,517

G

adiponectin, C1Q and collagen domain containing

decreases expression
increases expression
multiple interactions
increases secretion

Glucose results in decreased expression of ADIPOQ protein
Glucose results in increased expression of ADIPOQ protein
[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; Diethylhexyl Phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; Pioglitazone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]; tributyltin promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein]
Glucose deficiency results in increased secretion of ADIPOQ protein
ADIPOQ protein inhibits the reaction [Glucose results in decreased expression of ADIPOR2 protein]; argan oil promotes the reaction [Glucose results in increased expression of ADIPOQ protein]; Corn Oil promotes the reaction [Glucose results in increased expression of ADIPOQ protein]

PMID:21912612 PMID:24802182 PMID:29165388 PMID:32407875

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adiponectin receptor 1

multiple interactions
decreases expression

FOXO1 protein inhibits the reaction [Glucose results in decreased expression of ADIPOR1 mRNA]; FOXO1 protein inhibits the reaction [Glucose results in decreased expression of ADIPOR1 protein]; FOXO1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 mRNA]]; FOXO1 protein promotes the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 protein]]; Resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 mRNA]; Resveratrol inhibits the reaction [Glucose results in decreased expression of ADIPOR1 protein]
Glucose results in decreased expression of ADIPOR1 mRNA; Glucose results in decreased expression of ADIPOR1 protein

NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241

G

adiponectin receptor 2

multiple interactions
decreases expression

ADIPOQ protein inhibits the reaction [Glucose results in decreased expression of ADIPOR2 protein]

NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355

G

adrenoceptor alpha 1A

multiple interactions

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; 2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]; [cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose; [Phenylephrine results in increased activity of ADRA1A protein] which results in increased transport of Glucose; Prazosin inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose]

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

adrenoceptor beta 2

multiple interactions

[BRL 37344 binds to and results in increased activity of ADRB2 protein] which results in increased uptake of Glucose; [Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose; ICI 118551 inhibits the reaction [[BRL 37344 binds to and results in increased activity of ADRB2 protein] which results in increased uptake of Glucose]; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose]

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

[BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in decreased abundance of Glucose; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ADRB3 mRNA

PMID:20930473 PMID:37567420

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

alpha-fetoprotein

increases expression

Glucose results in increased expression of AFP mRNA

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

AGBL carboxypeptidase 4

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of AGBL4 mRNA

NCBI chr 5:125,254,963...126,534,367
Ensembl chr 5:125,254,956...126,534,367

G

advanced glycosylation end product-specific receptor

multiple interactions
increases expression

GLO1 inhibits the reaction [Glucose promotes the reaction [RELA protein binds to AGER promoter]]; GLO1 inhibits the reaction [Glucose results in increased expression of AGER mRNA]; GLO1 inhibits the reaction [Glucose results in increased expression of AGER protein]; Glucose promotes the reaction [RELA protein binds to AGER promoter]; Luteolin inhibits the reaction [Glucose results in increased expression of AGER mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of AGER mRNA]; RELA promotes the reaction [Glucose results in increased expression of AGER mRNA]; Rutin inhibits the reaction [Glucose results in increased expression of AGER mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of AGER mRNA]; SOD2 inhibits the reaction [Glucose results in increased expression of AGER protein]; UCP1 inhibits the reaction [Glucose results in increased expression of AGER mRNA]; UCP1 inhibits the reaction [Glucose results in increased expression of AGER protein]
[Ribose co-treated with Glucose] results in increased expression of AGER protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]
Glucose results in increased expression of AGER mRNA; Glucose results in increased expression of AGER protein
AGER protein results in increased susceptibility to [Azoxymethane co-treated with Glucose co-treated with Linoleic Acid]; Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]; Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Losartan inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Losartan inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]

PMID:19557821 PMID:19759273 PMID:19833897 PMID:22467055 PMID:30101366

NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078

G

amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase

increases uptake

AGL protein results in increased uptake of Glucose

NCBI chr 2:204,705,053...204,760,966
Ensembl chr 2:204,705,053...204,760,828

G

angiotensinogen

multiple interactions
increases expression
affects metabolic processing

(3,4-dihydroxyphenylamino)-2-imidazoline inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; acetovanillone inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; Enalaprilat inhibits the reaction [Glucose results in increased expression of AGT protein]; Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]; Glucose promotes the reaction [AGT protein results in increased expression of EGR1 mRNA]; Glucose promotes the reaction [AGT protein results in increased expression of FOSL1 mRNA]; Glucose promotes the reaction [AGT protein results in increased expression of KLF10 mRNA]; Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]; Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]; Rotenone inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of EGR1 mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of KLF10 mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased phosphorylation of JAK2 protein]]
Glucose results in increased expression of AGT mRNA; Glucose results in increased expression of AGT protein
AGT protein affects the metabolism of Glucose
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Glucose results in increased expression of AGT mRNA]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Glucose results in increased expression of AGT protein]; alpha-cyano-4-hydroxycinnamate inhibits the reaction [Glucose results in increased expression of AGT mRNA]; alpha-cyano-4-hydroxycinnamate inhibits the reaction [Glucose results in increased expression of AGT protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT protein]; CAT protein inhibits the reaction [Glucose results in increased expression of AGT mRNA]; CAT protein inhibits the reaction [Glucose results in increased expression of AGT protein]; Hydrogen Peroxide promotes the reaction [Glucose results in increased expression of AGT mRNA]; Hydrogen Peroxide promotes the reaction [Glucose results in increased expression of AGT protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of AGT mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of AGT protein]; NFE2L2 protein affects the reaction [Glucose results in increased expression of AGT mRNA]; oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]]; Rotenone inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Rotenone inhibits the reaction [Glucose results in increased expression of AGT protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of AGT mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of AGT protein]; Taurine inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Taurine inhibits the reaction [Glucose results in increased expression of AGT protein]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Thenoyltrifluoroacetone inhibits the reaction [Glucose results in increased expression of AGT protein]; trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Valsartan promotes the reaction [Glucose results in increased expression of AGT protein]

PMID:11115780 PMID:12130563 PMID:15677497 PMID:16452552 PMID:19225232 More...

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

increases expression
multiple interactions

Glucose results in increased expression of AGTR1 mRNA; Glucose results in increased expression of AGTR1 protein
CEBPB protein inhibits the reaction [Glucose results in increased expression of AGTR1 protein]
Enalaprilat inhibits the reaction [Glucose results in increased expression of AGTR1 protein]

PMID:16452552 PMID:29266779 PMID:31655124 PMID:34464088

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

angiotensin II receptor, type 2

multiple interactions
increases expression

CEBPB protein inhibits the reaction [Glucose results in increased expression of AGTR2 protein]

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

aryl hydrocarbon receptor

multiple interactions
increases response to substance

4,7-phenanthroline inhibits the reaction [AHR promotes the reaction [Tetrachlorodibenzodioxin results in decreased uptake of Glucose]]; AHR promotes the reaction [Tetrachlorodibenzodioxin results in decreased uptake of Glucose]; alpha-naphthoflavone inhibits the reaction [AHR promotes the reaction [Tetrachlorodibenzodioxin results in decreased uptake of Glucose]]
AHR results in increased susceptibility to Glucose
AHR protein promotes the reaction [Tetrachlorodibenzodioxin affects the susceptibility to Glucose]

PMID:8738555 PMID:19623578 PMID:21849270

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

allograft inflammatory factor 1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

apoptosis inducing factor, mitochondria associated 1

affects localization
multiple interactions

Glucose affects the localization of AIFM1 protein
Quercetin affects the reaction [Glucose affects the localization of AIFM1 protein]; sesamin affects the reaction [Glucose affects the localization of AIFM1 protein]

PMID:19146853 PMID:22524206

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

adenylate kinase 8

increases expression
multiple interactions

Glucose results in increased expression of AK8 mRNA
fucoxanthin inhibits the reaction [Glucose results in increased expression of AK8 mRNA]

NCBI chr 3:12,028,895...12,144,468
Ensembl chr 3:12,028,954...12,144,465

G

A-kinase anchoring protein 5

increases expression

Glucose results in increased expression of AKAP5 mRNA

NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578

G

aldo-keto reductase family 1 member A1

multiple interactions
decreases expression

fidarestat inhibits the reaction [Glucose results in decreased expression of AKR1A1 mRNA]

NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674

G

aldo-keto reductase family 1 member B1

multiple interactions
increases expression

AKR1B1 protein promotes the reaction [Glucose results in increased abundance of Sorbitol]
Glucose results in increased expression of AKR1B1 mRNA; Glucose results in increased expression of AKR1B1 protein

PMID:16805838 PMID:25451566

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1, member C1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of AKR1C6 mRNA

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C3

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of AKR1C18 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

increases phosphorylation
increases expression
decreases phosphorylation
multiple interactions
decreases expression
increases response to substance

Glucose results in increased phosphorylation of AKT1 protein
Glucose results in increased expression of AKT1 mRNA
Glucose results in decreased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [diallyl trisulfide inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]; 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; [3,4-Dihydroxyphenylacetic Acid co-treated with Glucose] results in increased phosphorylation of AKT1 protein; [Catechin co-treated with Glucose] results in increased phosphorylation of AKT1 protein; [Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein; Acetylcysteine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Acetylcysteine inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; diallyl trisulfide inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Glucose co-treated with Calcitriol] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency] which results in increased phosphorylation of EIF4EBP1 protein; [Glucose co-treated with Calcitriol] results in increased phosphorylation of AKT1 protein; AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; AKT1 protein modified form inhibits the reaction [arsenite inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; AKT1 protein modified form inhibits the reaction [monomethylarsonous acid inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; AKT1 protein promotes the reaction [Glucose affects the phosphorylation of and affects the activity of FOXO3 protein]; Bezafibrate inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; Glucose affects the phosphorylation of and affects the activity of AKT1 protein; methyl pyruvate inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; PRKAA2 protein affects the reaction [AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form affects the susceptibility to Glucose deficiency]]; SMARCA4A protein inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosiglitazone inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; [Glucose affects the susceptibility to INS protein] which affects the phosphorylation of AKT1 protein; [Palmitic Acid co-treated with Glucose] results in increased phosphorylation of AKT1 protein; ACACB protein affects the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; albiflorin inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased phosphorylation of AKT1 protein]; Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Captopril inhibits the reaction [Glucose results in increased expression of AKT1 mRNA]; Fluorometholone inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Glucose inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; HAGLR protein affects the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; HAGLR protein inhibits the reaction [MIR106B inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; huai qi huang inhibits the reaction [Glucose results in increased expression of AKT1 mRNA]; Metformin inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; MIR106B inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]]; PTEN protein affects the reaction [HAGLR protein affects the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; Rosiglitazone inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]; zhenwu decoction inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased phosphorylation of AKT1 protein]

PMID:15806154 PMID:16385087 PMID:17520061 PMID:18004065 PMID:20370652 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 2

affects response to substance

AKT2 protein affects the susceptibility to Glucose

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

albumin

multiple interactions
decreases uptake
increases metabolic processing

[Fructose co-treated with Glucose] results in increased glycation of ALB protein; [Peroxynitrous Acid co-treated with Glucose] results in increased glycation of ALB protein; Phlorhizin inhibits the reaction [Glucose results in decreased uptake of ALB protein]; pimagedine inhibits the reaction [[Fructose co-treated with Glucose] results in increased glycation of ALB protein]; pimagedine inhibits the reaction [[Peroxynitrous Acid co-treated with Glucose] results in increased glycation of ALB protein]; ursonic acid inhibits the reaction [[Fructose co-treated with Glucose] results in increased glycation of ALB protein]
ALB protein modified form inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]; ALB protein modified form inhibits the reaction [Glucose results in increased secretion of INS1 protein]; MK615 extract inhibits the reaction [ALB protein modified form inhibits the reaction [Glucose results in increased phosphorylation of RELA protein]]; MK615 extract inhibits the reaction [ALB protein modified form inhibits the reaction [Glucose results in increased secretion of INS1 protein]]
[Glucose deficiency co-treated with ALB protein] results in decreased expression of FABP4 mRNA; [Glucose deficiency co-treated with ALB protein] results in decreased expression of PCK1 mRNA
Glucose results in increased metabolism of ALB protein

PMID:8536680 PMID:12196478 PMID:12434198 PMID:16313995 PMID:27415824 More...

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

activated leukocyte cell adhesion molecule

multiple interactions
increases expression

fucoxanthin inhibits the reaction [Glucose results in increased expression of ALCAM mRNA]

NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954

G

aldehyde dehydrogenase 1 family, member B1

increases expression

Glucose deficiency results in increased expression of ALDH1B1 protein

NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378

G

aldehyde dehydrogenase 1 family, member L2

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of ALDH1L2 mRNA

NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776

G

aldehyde dehydrogenase 2 family member

decreases expression
multiple interactions

Glucose results in decreased expression of ALDH2 protein
N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ALDH2 protein]

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 3 family, member B3

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ALDH3B3 mRNA

NCBI chr 1:201,193,832...201,201,666
Ensembl chr 1:201,187,962...201,250,204

G

aldehyde dehydrogenase 6 family, member A1

decreases expression

Glucose results in decreased expression of ALDH6A1 mRNA

NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656

G

aldolase, fructose-bisphosphate C

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of ALDOA mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

ALG12, alpha-1,6-mannosyltransferase

decreases expression

Glucose results in decreased expression of ALG12 mRNA

NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458

G

ALK receptor tyrosine kinase

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ALK mRNA

NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034

G

arachidonate 12-lipoxygenase, 12S type

increases expression

Glucose results in increased expression of ALOX12 mRNA

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

arachidonate 5-lipoxygenase

multiple interactions
increases expression

[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein; caffeic acid inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; Edaravone inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; SB 203580 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]
Glucose results in increased expression of ALOX5 mRNA

PMID:18951527 PMID:31655124

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

alpha-kinase 3

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ALPK3 mRNA

NCBI chr 1:135,014,455...135,062,294
Ensembl chr 1:135,014,499...135,062,302

G

alkaline phosphatase, biomineralization associated

decreases expression
multiple interactions

Glucose results in decreased expression of ALPL mRNA
morroniside inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL protein]]; Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]]; Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]]

PMID:32643284 PMID:33450223

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

APC membrane recruitment protein 2

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of AMER2 mRNA

NCBI chr15:34,525,352...34,535,660
Ensembl chr15:34,524,542...34,528,455

G

angiomotin

decreases expression

Glucose results in decreased expression of AMOT mRNA

NCBI chr X:108,982,399...109,041,265
Ensembl chr X:108,984,022...109,041,272

G

angiopoietin-like 4

increases expression

Glucose results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin repeat domain 61

decreases expression
multiple interactions

Glucose results in decreased expression of ANKRD61 mRNA
fucoxanthin inhibits the reaction [Glucose results in decreased expression of ANKRD61 mRNA]

PMID:31525975 PMID:33448797

NCBI chr12:10,718,908...10,723,267
Ensembl chr12:10,718,908...10,723,265

G

ankyrin repeat and sterile alpha motif domain containing 1B

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ANKS1B mRNA

NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693

G

annexin A5

decreases expression

Glucose results in decreased expression of ANXA5 mRNA

NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369

G

amine oxidase, copper containing 1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of AOC1 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of AOC1 mRNA

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

apoptotic peptidase activating factor 1

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA]

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

APC regulator of WNT signaling pathway

decreases expression

Glucose results in decreased expression of APC mRNA

NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696

G

amyloid P component, serum

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of APCS mRNA

NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298

G

apolipoprotein A1

increases expression
decreases expression

Glucose results in increased expression of APOA1 mRNA; Glucose results in increased expression of APOA1 protein
Glucose results in decreased expression of APOA1 mRNA

PMID:9322794 PMID:9668074

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein B

multiple interactions

Glucose promotes the reaction [Copper Sulfate results in increased cleavage of APOB protein]

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein E

affects secretion
decreases expression
multiple interactions

Glucose deficiency affects the secretion of APOE protein
Glucose results in decreased expression of APOE mRNA; Glucose results in decreased expression of APOE protein
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of APOE mRNA; morroniside inhibits the reaction [Glucose results in decreased expression of APOE mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of APOE protein]

PMID:24802182 PMID:34485530 PMID:37567420

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

apolipoprotein L9a

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of APOL9A mRNA

NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649

G

amyloid beta precursor protein

multiple interactions
increases abundance

[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of Glucose; [APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Glucose; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Glucose]
APP protein mutant form results in increased abundance of Glucose
PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Glucose]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 1

increases expression
multiple interactions

Glucose results in increased expression of AQP1 mRNA
benazepril inhibits the reaction [Glucose results in increased expression of AQP1 mRNA]; valsartan inhibits the reaction [Glucose results in increased expression of AQP1 mRNA]

NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690

G

aquaporin 3 (Gill blood group)

multiple interactions
increases expression

Glucose promotes the reaction [AQP3 protein results in increased transport of Glycerol]
Glucose results in increased expression of AQP3 mRNA; Glucose results in increased expression of AQP3 protein

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

aquaporin 4

multiple interactions
increases expression

benazepril inhibits the reaction [Glucose results in increased expression of AQP4 mRNA]; valsartan inhibits the reaction [Glucose results in increased expression of AQP4 mRNA]

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

aquaporin 5

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of AQP5 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of AQP5 mRNA

NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209

G

aquaporin 8

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of AQP8 mRNA

NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158

G

androgen receptor

multiple interactions

[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of AR mRNA; tetrahydropalmatine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of AR mRNA]
[2,4-Dichlorophenoxyacetic Acid co-treated with Glyphosate co-treated with lard co-treated with Cholesterol co-treated with Glucose co-treated with Sucrose co-treated with Fructose] results in decreased expression of AR protein

PMID:37606869 PMID:37615203

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

arginase 2

increases expression

Glucose results in increased expression of ARG2 mRNA

NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378

G

Rho GTPase activating protein 6

increases expression

Glucose results in increased expression of ARHGAP6 mRNA

NCBI chr X:24,953,464...25,490,003
Ensembl chr X:24,953,464...25,488,663

G

Rho GDP dissociation inhibitor beta

decreases expression
multiple interactions

Glucose results in decreased expression of ARHGDIB mRNA
fucoxanthin inhibits the reaction [Glucose results in decreased expression of ARHGDIB mRNA]

NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658

G

ARF like GTPase 4D

multiple interactions

[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of ARL4D mRNA; ARL4D protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]

NCBI chr10:86,592,054...86,602,843
Ensembl chr10:86,595,661...86,602,836

G

ARF like GTPase 5B

increases expression

Glucose results in increased expression of ARL5B mRNA

NCBI chr17:77,955,864...77,979,895
Ensembl chr17:77,955,818...77,979,854

G

ARF like GTPase 5C

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of ARL5C mRNA

NCBI chr10:82,985,213...82,993,425
Ensembl chr10:82,985,216...82,992,002

G

armadillo repeat containing, X-linked 6

multiple interactions
increases expression

fucoxanthin inhibits the reaction [Glucose results in increased expression of ARMCX6 mRNA]

NCBI chr X:97,929,032...97,932,031
Ensembl chr X:97,929,041...97,931,977

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions
increases activity

[Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA; Glucose promotes the reaction [[ARNT protein binds to G6PC1 promoter] which results in increased expression of G6PC1 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA]
Glucose results in increased activity of ARNT protein
[Glucose co-treated with Oxygen deficiency] inhibits the reaction [ARNT protein binds to HIF1A protein]

PMID:15767253 PMID:18227068 PMID:33962019

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

arylsulfatase family, member J

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of ARSJ mRNA

NCBI chr 2:214,774,631...214,854,614
Ensembl chr 2:214,774,654...214,854,612

G

achaete-scute family bHLH transcription factor 1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ASCL1 mRNA

NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993

G

asparagine synthetase (glutamine-hydrolyzing)

affects expression

Glucose affects the expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

asparaginase

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in decreased expression of ASPG mRNA

NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268

G

asporin

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of ASPN mRNA

NCBI chr17:15,079,910...15,104,369
Ensembl chr17:15,080,639...15,104,041

G

ATPase family, AAA domain containing 1

multiple interactions

ATAD1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]

NCBI chr 1:230,544,227...230,610,524
Ensembl chr 1:230,544,047...230,596,548

G

activating transcription factor 3

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

increases expression
increases response to substance
multiple interactions

Glucose deficiency results in increased expression of ATF4 mRNA
ATF4 protein results in increased susceptibility to Glucose
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ATF4 protein]
Glucose deficiency results in increased expression of ATF4 protein
4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of ATF4 protein]; [Galactose co-treated with Glucose deficiency] promotes the reaction [Leflunomide results in increased expression of ATF4 protein]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of ATF4 protein]]

PMID:27226639 PMID:27278863 PMID:29427785 PMID:31022492 PMID:34801538

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

increases expression
multiple interactions

Glucose deficiency results in increased expression of ATF6 protein
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of ATF6 protein]; Glucose results in increased expression of and affects the localization of ATF6 protein; Metformin inhibits the reaction [Glucose results in increased expression of and affects the localization of ATF6 protein]
4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of ATF6 protein]; ATF6 protein modified form promotes the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]]

PMID:31022492 PMID:34801538

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

autophagy related 10

increases expression
multiple interactions

Glucose results in increased expression of ATG10 mRNA
fucoxanthin inhibits the reaction [Glucose results in increased expression of ATG10 mRNA]

NCBI chr 2:22,109,304...22,398,313
Ensembl chr 2:22,108,426...22,398,233

G

autophagy related 3

increases expression

Glucose results in increased expression of ATG3 mRNA

NCBI chr11:55,624,914...55,653,249
Ensembl chr11:55,624,917...55,653,224

G

autophagy related 5

multiple interactions
increases expression
decreases expression

3-methyladenine inhibits the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]]; [Glucose co-treated with Lycopene] results in increased expression of ATG5 mRNA; N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]]; ULK1 protein affects the reaction [Glucose results in decreased expression of ATG5 protein]; ULK1 protein affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]]
Glucose results in increased expression of ATG5 mRNA

PMID:29128638 PMID:38444079

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

multiple interactions
decreases expression

Inositol inhibits the reaction [Glucose results in decreased expression of ATG7 protein]

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

atlastin GTPase 1

multiple interactions

ATL1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]

NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204

G

antioxidant 1 copper chaperone

increases expression

Glucose results in increased expression of ATOX1 mRNA

NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions

Glucose results in decreased expression of and results in decreased activity of ATP1A1 protein; INS protein inhibits the reaction [Glucose results in decreased expression of ATP1A1 protein]
[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of and affects the localization of ATP1A1 protein; Antigen-Antibody Complex inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of and affects the localization of ATP1A1 protein]

PMID:22162761 PMID:29702141

NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

decreases expression
multiple interactions

Glucose results in decreased expression of ATP2A1 mRNA
fucoxanthin inhibits the reaction [Glucose results in decreased expression of ATP2A1 mRNA]

PMID:31525975 PMID:33448797

NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838

G

ATP synthase F1 subunit alpha

multiple interactions

[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of ATP5F1A protein

NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794

G

ATP synthase F1 subunit delta

multiple interactions

15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]]; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]; Y 27632 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]

NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929

G

ATPase H+ transporting accessory protein 2

increases expression
multiple interactions

Glucose results in increased expression of ATP6AP2 mRNA; Glucose results in increased expression of ATP6AP2 protein
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Glucose results in increased expression of ATP6AP2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Glucose results in increased expression of ATP6AP2 protein]

NCBI chr X:10,183,983...10,210,948
Ensembl chr X:10,183,068...10,210,918

G

aurora kinase A

increases expression

Glucose results in increased expression of AURKA mRNA

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

alpha-2-glycoprotein 1, zinc-binding

affects secretion

Glucose deficiency affects the secretion of AZGP1 protein

NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091

G

beta-2 microglobulin

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of B2M mRNA

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

beta-1,3-glucuronyltransferase 3

increases expression
multiple interactions

Glucose results in increased expression of B3GAT3 mRNA
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA]; IL1B protein inhibits the reaction [Glucose results in increased expression of B3GAT3 mRNA]

NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of B3GNT6 mRNA

NCBI chr 1:152,484,572...152,496,226
Ensembl chr 1:152,486,343...152,492,150

G

beta-1,4-N-acetyl-galactosaminyl transferase 4

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of B4GALNT4 mRNA

NCBI chr 1:196,171,394...196,182,294
Ensembl chr 1:196,171,394...196,182,294

G

BCL2-associated agonist of cell death

multiple interactions
increases expression

[resveratrol results in increased activity of SIRT1 protein] inhibits the reaction [Glucose results in decreased phosphorylation of and results in decreased activity of BAD protein]; Glucose results in decreased phosphorylation of and results in decreased activity of BAD protein
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAD protein
Glucose results in increased expression of BAD mRNA

PMID:17293559 PMID:20370652 PMID:38444079

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2-antagonist/killer 1

multiple interactions
increases expression

[[Oxygen deficiency co-treated with Glucose deficiency] results in increased susceptibility to Carvedilol] which results in decreased expression of BAK1 mRNA
Glucose results in increased expression of BAK1 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA]

PMID:29122578 PMID:33962019 PMID:38444079

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BMP and activin membrane-bound inhibitor

multiple interactions
increases expression

fucoxanthin inhibits the reaction [Glucose results in increased expression of BAMBI mRNA]

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060

G

BARX homeobox 2

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of BARX2 mRNA

NCBI chr 8:30,251,132...30,319,105
Ensembl chr 8:30,251,132...30,319,013

G

basic leucine zipper ATF-like transcription factor 2

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of BATF2 mRNA

NCBI chr 1:203,467,291...203,479,428
Ensembl chr 1:203,468,097...203,475,889

G

BCL2 associated X, apoptosis regulator

increases expression
affects expression
multiple interactions

Glucose results in increased expression of BAX mRNA; Glucose results in increased expression of BAX protein
Glucose affects the expression of BAX protein
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Glucose results in increased expression of BAX protein]; [Dithionite co-treated with Glucose deficiency] results in increased expression of BAX protein; [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in increased expression of BAX protein]; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of BAX protein]]; cinnamic acid inhibits the reaction [Glucose results in increased expression of BAX protein]; Diosgenin inhibits the reaction [Glucose results in increased expression of BAX protein]; dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of BAX protein]]; gastrodin inhibits the reaction [Glucose results in increased expression of BAX protein]; Metformin inhibits the reaction [Glucose results in increased expression of BAX protein]; morroniside inhibits the reaction [Glucose results in increased expression of BAX protein]; naringenin inhibits the reaction [Glucose results in increased expression of BAX mRNA]; naringenin inhibits the reaction [Glucose results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein]; Quercetin affects the reaction [Glucose affects the expression of BAX protein]; Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in increased expression of BAX protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of BAX protein]; Scopoletin inhibits the reaction [Glucose results in increased expression of BAX protein]; sesamin affects the reaction [Glucose affects the expression of BAX protein]; STIM1 protein affects the reaction [Glucose results in increased expression of BAX protein]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX mRNA]]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX mRNA]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of BAX protein]; [Glucose co-treated with Bupivacaine] results in increased expression of BAX protein; [Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX mRNA; [Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein modified form; CEBPB protein inhibits the reaction [Glucose results in increased expression of BAX protein]; gastrodin inhibits the reaction [Glucose results in increased expression of BAX protein]; HIF1A protein affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]]; Isoflurane inhibits the reaction [2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX mRNA]]; Isoflurane inhibits the reaction [2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]]; Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX mRNA]; Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of BAX protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]; U 0126 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]; Valsartan inhibits the reaction [Glucose results in increased expression of BAX protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein]]; [Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased expression of BAX mRNA]; [Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of BAX protein; asiatic acid inhibits the reaction [Glucose results in increased expression of BAX mRNA]; Carnosine inhibits the reaction [Glucose results in increased expression of BAX mRNA]; diallyl trisulfide inhibits the reaction [Glucose results in increased expression of BAX protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX protein]; MIR142 affects the reaction [TAOK1 mRNA alternative form affects the reaction [Glucose results in increased expression of BAX protein]]; MIR142 inhibits the reaction [Glucose results in increased expression of BAX protein]; MitoTEMPO inhibits the reaction [Glucose results in increased expression of BAX protein]; NDRG2 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]; polyethylene glycol loxenatide inhibits the reaction [Glucose results in increased expression of BAX protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of BAX protein]; salvianolic acid inhibits the reaction [Glucose results in increased expression of BAX protein]; SOX6 protein inhibits the reaction [MIR142 inhibits the reaction [Glucose results in increased expression of BAX protein]]; spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein]; TAOK1 mRNA alternative form affects the reaction [Glucose results in increased expression of BAX protein]

PMID:21803128 PMID:22524206 PMID:23192364 PMID:23451161 PMID:24218232 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA; [Palmitic Acid co-treated with Glucose] results in increased expression of BBC3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA]; SIRT1 protein mutant form inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased expression of BBC3 mRNA]
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BBC3 protein modified form; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BBC3 protein]

PMID:24451382 PMID:28675767 PMID:33962019

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

butyrylcholinesterase

multiple interactions
increases expression

fucoxanthin inhibits the reaction [Glucose results in increased expression of BCHE mRNA]

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

BCL11 transcription factor A

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of BCL11A mRNA

NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180

G

BCL2, apoptosis regulator

decreases expression
multiple interactions
affects expression

Glucose results in decreased expression of BCL2 mRNA; Glucose results in decreased expression of BCL2 protein
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 mRNA]]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 mRNA]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein]; [Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein; [Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 mRNA; [Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]]; gastrodin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; HIF1A protein affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]]; Isoflurane inhibits the reaction [2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 mRNA]]; Isoflurane inhibits the reaction [2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]]; Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 mRNA]; Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]; MIR210 mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 mRNA]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]; U 0126 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA; [Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein; [Resveratrol co-treated with Glucose] results in increased expression of BCL2 protein; asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; asiatic acid promotes the reaction [Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Carnosine inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; Carnosine promotes the reaction [asiatic acid inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]]; Catechin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; diallyl trisulfide inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; epigallocatechin gallate inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; Gliclazide inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]; Glucose results in increased degradation of and results in decreased expression of BCL2 protein; Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein]; MIR142 affects the reaction [TAOK1 mRNA alternative form affects the reaction [Glucose results in decreased expression of BCL2 protein]]; MIR142 inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; MitoTEMPO inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; polyethylene glycol loxenatide inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Quercetin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; Rutin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; salvianolic acid inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; SOX6 protein inhibits the reaction [MIR142 inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Tamoxifen inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; TAOK1 mRNA alternative form affects the reaction [Glucose results in decreased expression of BCL2 protein]
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; [Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein; [Glucose co-treated with Lycopene] results in increased expression of BCL2 mRNA; [Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of BCL2 protein]; [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein; [Oxygen deficiency co-treated with Glucose deficiency] affects the expression of BCL2 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein; Chlorogenic Acid inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; cinnamic acid inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Diosgenin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; dorsomorphin inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; gastrodin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Metformin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; morroniside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; naringenin inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; naringenin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]; Quercetin affects the reaction [Glucose affects the expression of BCL2 protein]; Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Scopoletin inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; sesamin affects the reaction [Glucose affects the expression of BCL2 protein]; STIM1 protein affects the reaction [Glucose results in decreased expression of BCL2 protein]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]
Glucose affects the expression of BCL2 mRNA; Glucose affects the expression of BCL2 protein

PMID:18088078 PMID:19557821 PMID:21413024 PMID:21803128 PMID:21818840 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

BCL2L1 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

Bcl2-like 11

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]]; resveratrol inhibits the reaction [Glucose results in increased expression of BCL2L11 protein]

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

Bcl2-like 15

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA]

NCBI chr 2:191,338,959...191,344,078
Ensembl chr 2:191,338,959...191,344,078

G

beta-carotene oxygenase 1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of BCO1 mRNA

NCBI chr19:45,149,250...45,186,102
Ensembl chr19:45,149,265...45,186,101

G

bradykinin receptor B1

increases expression
multiple interactions

Glucose results in increased expression of BDKRB1 protein
argan oil inhibits the reaction [Glucose results in increased expression of BDKRB1 protein]; Corn Oil inhibits the reaction [Glucose results in increased expression of BDKRB1 protein]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

beclin 1

multiple interactions
increases expression
decreases expression

[Glucose co-treated with Lycopene] results in increased expression of BECN1 mRNA; [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in decreased expression of BECN1 protein]; [Resveratrol co-treated with Glucose] results in increased expression of BECN1 protein; Inositol inhibits the reaction [Glucose results in decreased expression of BECN1 protein]
Glucose results in increased expression of BECN1 mRNA
Glucose results in increased expression of BECN1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in increased expression of BECN1 protein]]; Calcitriol inhibits the reaction [Glucose results in increased expression of BECN1 protein]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in increased expression of BECN1 protein]]; HU 308 inhibits the reaction [Glucose results in decreased expression of BECN1 protein]

PMID:25997894 PMID:28713934 PMID:30459625 PMID:33450223 PMID:35243728 More...

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

brain-enriched guanylate kinase-associated

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of BEGAIN mRNA

NCBI chr 6:127,943,651...127,979,876
Ensembl chr 6:127,943,651...127,979,841

G

bone gamma-carboxyglutamate protein

multiple interactions
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP protein]]; Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]; FOXO1 protein inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]]; Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]]
Glucose results in decreased expression of BGLAP mRNA; Glucose results in decreased expression of BGLAP protein
morroniside inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]; morroniside inhibits the reaction [Glucose results in decreased expression of BGLAP protein]

PMID:32643284 PMID:33450223

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

betaine-homocysteine S-methyltransferase

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of BHMT mRNA

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

BH3 interacting domain death agonist

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA]

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

bone morphogenetic protein 2

decreases expression
multiple interactions

Glucose results in decreased expression of BMP2 mRNA
morroniside inhibits the reaction [Glucose results in decreased expression of BMP2 mRNA]
cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of BMP2 mRNA]; tin mesoporphyrin promotes the reaction [Glucose results in decreased expression of BMP2 mRNA]

PMID:19924377 PMID:32643284

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

BMP-binding endothelial regulator

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of BMPER mRNA

NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256

G

BCL2 interacting protein 3

multiple interactions

[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA]

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BCL2 interacting protein 3 like

multiple interactions
decreases expression

[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA]
Glucose results in decreased expression of BNIP3L protein
Inositol inhibits the reaction [Glucose results in decreased expression of BNIP3L protein]

PMID:33962019 PMID:35243728

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

bone marrow stromal cell antigen 2

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of BST2 mRNA

NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979

G

BTB domain containing 17

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of BTBD17 mRNA

NCBI chr10:99,826,132...99,832,624
Ensembl chr10:99,826,132...99,832,624

G

C1q and TNF related 3

decreases expression

Glucose results in decreased expression of C1QTNF3 mRNA

NCBI chr 2:59,917,099...59,939,519
Ensembl chr 2:59,917,188...59,939,433

G

complement C1r

decreases secretion

Glucose deficiency results in decreased secretion of C1R protein

NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484

G

complement C1s

affects secretion

Glucose deficiency affects the secretion of C1S protein

NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303

G

complement C3

increases expression
multiple interactions

Glucose results in increased expression of C3 mRNA
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of C3 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of C3 mRNA; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of C3 mRNA

PMID:17178593 PMID:23199288 PMID:37567420

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

complement C4B

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of C4B mRNA

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

complement C5

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of HC mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of HC mRNA

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

complement C5a receptor 1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of C5AR1 mRNA

NCBI chr 1:76,948,622...76,959,826

G

calcium binding protein 4

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of CABP4 mRNA

NCBI chr 1:201,428,671...201,442,950
Ensembl chr 1:201,428,672...201,433,172

G

calcium voltage-gated channel subunit alpha1 S

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of CACNA1S mRNA

NCBI chr13:47,493,949...47,564,194
Ensembl chr13:47,493,949...47,564,318

G

calcitonin-related polypeptide alpha

increases expression
multiple interactions

Glucose results in increased expression of CALCA mRNA
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CALCA mRNA

PMID:31655124 PMID:37567420

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calmodulin 2

multiple interactions

CALM2 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]

NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287

G

calreticulin

decreases expression

Glucose results in decreased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calumenin

decreases secretion

Glucose deficiency results in decreased secretion of CALU protein

NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593

G

calcyon neuron-specific vesicular protein

multiple interactions

CALY protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]

NCBI chr 1:194,862,671...194,873,861
Ensembl chr 1:194,862,672...194,873,551

G

calnexin

decreases expression
increases expression
multiple interactions

Glucose results in decreased expression of CANX mRNA
Glucose results in increased expression of CANX protein
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of CANX protein]

PMID:17178593 PMID:34801538

NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821

G

calpain 1

multiple interactions
increases expression

2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside inhibits the reaction [[Oxygen co-treated with Glucose deficiency] results in increased expression of CAPN1 protein]; [Oxygen co-treated with Glucose deficiency] results in increased expression of CAPN1 protein
Furans analog inhibits the reaction [Glucose results in increased expression of CAPN1 protein]

PMID:24726522 PMID:28911973

NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177

G

carbonic anhydrase 3

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in increased expression of CAR3 mRNA

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

caspase 1

multiple interactions
increases cleavage
increases expression
increases activity

Acetylcysteine inhibits the reaction [Glucose results in increased cleavage of CASP1 protein]; FOXO3 protein promotes the reaction [Glucose results in increased cleavage of and results in increased activity of CASP1 protein]; Glucose results in increased cleavage of and results in increased activity of CASP1 protein; Glucose results in increased expression of and results in increased cleavage of CASP1 protein
Glucose results in increased expression of CASP1 mRNA
Glucose results in increased expression of CASP1 protein
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein modified form; Allopurinol inhibits the reaction [Glucose results in increased expression of CASP1 protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein modified form]; L 709049 analog inhibits the reaction [Glucose results in increased expression of CASP1 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of CASP1 protein]; rhodioloside inhibits the reaction [Glucose results in increased expression of CASP1 protein]; Suramin inhibits the reaction [Glucose results in increased activity of CASP1 protein]; TXNIP mRNA promotes the reaction [Glucose results in increased expression of CASP1 protein]
[Glucose co-treated with TGFB1 protein] results in increased cleavage of CASP1 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein; Allopurinol inhibits the reaction [Glucose results in increased expression of CASP1 protein]; aucubin inhibits the reaction [[Glucose co-treated with TGFB1 protein] results in increased cleavage of CASP1 protein]; bellidifolin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein]; Glucose results in increased expression of and results in increased cleavage of CASP1 protein; HAGLR protein affects the reaction [Glucose results in increased expression of and results in increased cleavage of CASP1 protein]; HAGLR protein promotes the reaction [Glucose results in increased expression of and results in increased cleavage of CASP1 protein]; L 709049 analog inhibits the reaction [Glucose results in increased expression of CASP1 protein]; Lipopolysaccharides inhibits the reaction [swietenine inhibits the reaction [Glucose results in increased expression of CASP1 protein]]; Lipopolysaccharides promotes the reaction [Glucose results in increased expression of CASP1 protein]; loganin inhibits the reaction [Glucose results in increased expression of CASP1 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of CASP1 protein]; MIR200C mRNA affects the reaction [Glucose results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Glucose results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [swietenine inhibits the reaction [Glucose results in increased expression of CASP1 protein]]; PTEN protein affects the reaction [HAGLR protein affects the reaction [Glucose results in increased expression of and results in increased cleavage of CASP1 protein]]; Quercetin inhibits the reaction [Glucose results in increased expression of CASP1 protein]; SLC30A7 protein affects the reaction [MIR200C mRNA affects the reaction [Glucose results in increased cleavage of CASP1 protein]]; swietenine inhibits the reaction [Glucose results in increased expression of CASP1 protein]; TXNIP mRNA promotes the reaction [Glucose results in increased expression of CASP1 protein]
Glucose results in increased expression of CASP1 mRNA; Glucose results in increased expression of CASP1 protein
Glucose results in increased activity of CASP1 mRNA; Glucose results in increased activity of CASP1 protein

PMID:20370652 PMID:21832250 PMID:23647015 PMID:27783111 PMID:29031534 More...

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 12

multiple interactions
increases expression
increases cleavage

TRPM7 protein affects the reaction [Glucose results in increased cleavage of CASP12 protein]; waixenicin A inhibits the reaction [Glucose results in increased cleavage of CASP12 protein]
Glucose results in increased expression of CASP12 protein
Chlorogenic Acid inhibits the reaction [Glucose results in increased expression of CASP12 protein]

PMID:30076216 PMID:34801538

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

multiple interactions
decreases expression
increases cleavage
increases expression
increases activity

[Carnosine co-treated with asiatic acid] inhibits the reaction [Glucose results in increased activity of CASP3 protein]; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein; [Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form; [Glucose deficiency co-treated with Acetylcysteine] results in increased activity of CASP3 protein; [Glucose deficiency co-treated with CAT] results in increased activity of CASP3 protein; [Glucose deficiency co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP3 protein; [Palmitic Acid co-treated with Glucose] results in increased cleavage of CASP3 protein; asiatic acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Captopril inhibits the reaction [Glucose results in increased expression of CASP3 mRNA]; Carnosine inhibits the reaction [Glucose results in increased activity of CASP3 protein]; diallyl trisulfide inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Fluorometholone inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Gliclazide inhibits the reaction [Glucose results in increased expression of CASP3 protein]; huai qi huang inhibits the reaction [Glucose results in increased expression of CASP3 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Glucose results in increased expression of CASP3 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein]; MIR142 affects the reaction [TAOK1 mRNA alternative form affects the reaction [Glucose results in increased cleavage of CASP3 protein]]; MIR142 inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; MitoTEMPO inhibits the reaction [Glucose results in increased activity of CASP3 protein]; polyethylene glycol loxenatide inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Rosiglitazone inhibits the reaction [Glucose results in increased activity of CASP3 protein]; rutecarpine inhibits the reaction [Glucose results in increased activity of CASP3 protein]; salvianolic acid inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; SIRT1 protein inhibits the reaction [[Palmitic Acid co-treated with Glucose] results in increased cleavage of CASP3 protein]; SOX6 protein inhibits the reaction [MIR142 inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; TAOK1 mRNA alternative form affects the reaction [Glucose results in increased cleavage of CASP3 protein]
Glucose results in decreased expression of CASP3 mRNA
Glucose results in increased expression of CASP3 mRNA; Glucose results in increased expression of CASP3 protein; Glucose results in increased expression of CASP3 protein modified form
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [2-chloro-N(6)cyclopentyladenosine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [LY 379268 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; 2-chloro-N(6)cyclopentyladenosine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; [Dithionite co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein; [Glucose co-treated with Lycopene] results in increased expression of CASP3 mRNA; [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein; [Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] affects the expression of and affects the activity of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [Glucose results in increased activity of CASP3]; Antigen-Antibody Complex inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; Chlorogenic Acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]; cinnamic acid inhibits the reaction [Glucose results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; diallyl trisulfide inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]; diallyl trisulfide inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Diosgenin inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]; gastrodin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Glucose results in increased expression of and results in increased activity of CASP3 protein; Glucose results in increased expression of and results in increased cleavage of CASP3 protein; GSK3B protein inhibits the reaction [MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; HMOX1 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; HMOX1 protein promotes the reaction [diallyl trisulfide inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; IGF2R protein modified form inhibits the reaction [Glucose results in increased expression of CASP3 protein modified form]; IGF2R protein modified form inhibits the reaction [Glucose results in increased expression of CASP3 protein]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; LY 379268 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; Metformin inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Metformin inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; MIR135A mRNA inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; morroniside inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased activity of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased expression of and results in increased cleavage of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased expression of CASP3 mRNA]; NFE2L2 mutant form inhibits the reaction [diallyl trisulfide inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; NFE2L2 protein mutant form affects the reaction [plumbagin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; NFE2L2 protein promotes the reaction [diallyl trisulfide inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]; plumbagin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; Propofol inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in increased expression of CASP3 protein]; Quercetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein]; Quercetin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of CASP3 mRNA]; Quercetin inhibits the reaction [Glucose results in increased expression of CASP3 protein modified form]; Scopoletin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; sesamin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; STAT3 protein affects the reaction [Propofol inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]]; STIM1 protein affects the reaction [Glucose results in increased cleavage of CASP3 protein]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [2-chloro-N(6)cyclopentyladenosine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [LY 379268 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; WDR35 protein affects the reaction [Glucose results in increased activity of CASP3 protein]; Y 27632 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]
Glucose results in increased activity of CASP3; Glucose results in increased activity of CASP3 protein
2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CASP3 mRNA]]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CASP3 mRNA]; [Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein; [Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CASP3 mRNA; [Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein; [Oxygen deficiency co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein; FOXO3 protein promotes the reaction [Glucose results in increased cleavage of and results in increased activity of CASP3 protein]; gastrodin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Glucose deficiency inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein modified form]; Glucose results in increased cleavage of and results in increased activity of CASP3 protein; HIF1A protein affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; HIF1A protein affects the reaction [MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]]; INO 1001 inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Isoflurane inhibits the reaction [2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]]; Isoflurane inhibits the reaction [2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide promotes the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CASP3 mRNA]]; Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; Isoflurane inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CASP3 mRNA]; MIR144 mRNA promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; MIR186 mRNA affects the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; MIR186 mRNA inhibits the reaction [[Glucose deficiency co-treated with Oxygen deficiency] results in increased cleavage of CASP3 protein]; MIR322 affects the reaction [Glucose results in increased cleavage of CASP3 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Glucose results in increased activity of CASP3 protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein]; SIRT7 protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; TRAF3 affects the reaction [Glucose results in increased cleavage of CASP3 protein]; TRPM7 protein affects the reaction [Glucose results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased cleavage of CASP3 protein]; VDAC1 protein inhibits the reaction [Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; VDAC1 protein promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]; waixenicin A inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein]

PMID:15322300 PMID:16135072 PMID:17065336 PMID:17293559 PMID:17309078 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity
increases expression
multiple interactions

Glucose results in increased activity of CASP8 protein
Glucose results in increased expression of CASP8 mRNA
[Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA]
[Glucose co-treated with Lycopene] results in increased expression of CASP8 mRNA; Acetylcysteine inhibits the reaction [Glucose results in increased activity of CASP8]

PMID:18791325 PMID:18973755 PMID:33962019 PMID:38444079

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases cleavage
increases expression
increases activity

[Glucose deficiency co-treated with Acetylcysteine] results in increased activity of CASP9 protein; [Glucose deficiency co-treated with CAT] results in increased activity of CASP9 protein; [Glucose deficiency co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP9 protein; salvianolic acid inhibits the reaction [Glucose results in increased cleavage of CASP9 protein]
Glucose results in increased expression of CASP9 mRNA; Glucose results in increased expression of CASP9 protein
[Glucose co-treated with IGF2R protein modified form] results in increased expression of CASP9 protein; [Glucose co-treated with Lycopene] results in increased expression of CASP9 mRNA; [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Glucose results in increased activity of CASP9]; Glucose results in increased expression of and results in increased cleavage of CASP9 protein; naringenin inhibits the reaction [Glucose results in increased expression of and results in increased cleavage of CASP9 protein]; naringenin inhibits the reaction [Glucose results in increased expression of CASP9 mRNA]; Scopoletin inhibits the reaction [Glucose results in increased expression of CASP9 protein]

PMID:17309078 PMID:18791325 PMID:23192364 PMID:25997894 PMID:30431688 More...

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

castor zinc finger 1

increases expression
multiple interactions

Glucose results in increased expression of CASZ1 mRNA
fucoxanthin inhibits the reaction [Glucose results in increased expression of CASZ1 mRNA]

NCBI chr 5:159,243,965...159,393,935
Ensembl chr 5:159,243,995...159,393,400

G

catalase

multiple interactions
decreases activity
increases activity
increases expression
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein]]; [Glucose deficiency co-treated with CAT] affects the localization of ENDOG protein; [Glucose deficiency co-treated with CAT] results in increased activity of CASP3 protein; [Glucose deficiency co-treated with CAT] results in increased activity of CASP9 protein; [Glucose deficiency co-treated with CAT] results in increased cleavage of PARP1 protein; CAT inhibits the reaction [Glucose deficiency affects the folding of SOD2 protein]; CAT inhibits the reaction [Glucose deficiency results in increased activity of MAPK1 protein]; CAT inhibits the reaction [Glucose deficiency results in increased activity of MAPK14 protein]; CAT inhibits the reaction [Glucose deficiency results in increased activity of MAPK3 protein]; CAT inhibits the reaction [Glucose deficiency results in increased degradation of SOD1 protein]; CAT protein inhibits the reaction [Glucose promotes the reaction [EDN1 protein results in increased chemical synthesis of Inositol 1,4,5-Trisphosphate]]; cyclopamine inhibits the reaction [SHH protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]]; Furans analog inhibits the reaction [Glucose results in decreased activity of CAT protein]; SHH protein inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]; SIRT3 protein inhibits the reaction [Glucose results in increased expression of CAT protein]; solanesol inhibits the reaction [Glucose results in decreased activity of CAT protein]; spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein]
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [gastrodin inhibits the reaction [Glucose results in decreased activity of CAT protein]]; [Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein; cyclopamine inhibits the reaction [polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]]; cyclopamine promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]; gastrodin inhibits the reaction [Glucose results in decreased activity of CAT protein]; NFE2L2 protein affects the reaction [gastrodin inhibits the reaction [Glucose results in decreased activity of CAT protein]]; polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]
Glucose deficiency results in increased expression of CAT protein; Glucose results in increased expression of CAT protein
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [gastrodin inhibits the reaction [Glucose results in decreased activity of CAT protein]]; [Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in decreased activity of CAT protein; CAT protein inhibits the reaction [Glucose results in increased expression of AGT mRNA]; CAT protein inhibits the reaction [Glucose results in increased expression of AGT protein]; CAT protein inhibits the reaction [Glucose results in increased expression of GNA11 protein]; CAT protein inhibits the reaction [Glucose results in increased expression of GNAQ protein]; CAT protein inhibits the reaction [Glucose results in increased expression of PLCB1 protein]; CAT protein inhibits the reaction [Glucose results in increased expression of PLCB2 protein]; gastrodin inhibits the reaction [Glucose results in decreased activity of CAT protein]; naringenin inhibits the reaction [Glucose results in decreased activity of CAT protein]; NFE2L2 protein affects the reaction [gastrodin inhibits the reaction [Glucose results in decreased activity of CAT protein]]; Resveratrol inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency co-treated with Oxygen] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [Glucose results in decreased activity of CAT protein]
Glucose results in decreased expression of CAT mRNA

PMID:12130563 PMID:17309078 PMID:20691780 PMID:21818840 PMID:23192364 More...

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

decreases expression
multiple interactions

Glucose results in decreased expression of CAV1 mRNA; Glucose results in decreased expression of CAV1 protein
EGF protein inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA]; Simvastatin inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA]

PMID:19816600 PMID:31655124

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

carbonyl reductase 3

increases expression

Glucose results in increased expression of CBR3 mRNA

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

cystathionine beta synthase

increases expression
decreases expression

Glucose results in increased expression of CBS mRNA
Glucose deficiency results in decreased expression of CBS mRNA

PMID:17178593 PMID:35577173

NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764

G

coiled-coil domain containing 116

multiple interactions
decreases expression

fucoxanthin inhibits the reaction [Glucose results in decreased expression of CCDC116 mRNA]

NCBI chr11:83,842,707...83,850,607
Ensembl chr11:83,845,557...83,850,607

G

coiled-coil domain containing 169

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CCDC169 mRNA

NCBI chr 2:139,321,644...139,351,161
Ensembl chr 2:139,321,670...139,351,161

G

coiled-coil domain containing 190

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of CCDC190 mRNA

NCBI chr13:82,147,161...82,154,863
Ensembl chr13:82,147,176...82,154,863

G

C-C motif chemokine ligand 2

increases expression
multiple interactions
increases secretion

Glucose results in increased expression of CCL2 mRNA; Glucose results in increased expression of CCL2 protein
(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CCL2 protein]; [Glucose co-treated with fatostatin] results in increased expression of CCL2 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL2 mRNA; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; [Resveratrol affects the localization of RELA protein] inhibits the reaction [Glucose results in increased expression of CCL2 protein]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; aspalathin inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; aspalathin inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Aspirin inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Aspirin inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Aspirin inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Bezafibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; CCL2 mRNA affects the reaction [Glucose results in increased expression of CCN2 protein]; chromic chloride inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; chromium nicotinic acid complex inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Clofibrate inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Clofibrate inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Clofibrate inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; diphenyleneiodonium inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; diphenyleneiodonium inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; Fenofibrate inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Fenofibrate inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Fenofibrate inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Glucose inhibits the reaction [Fructose results in increased secretion of CCL2 protein]; Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]; HTS 466284 inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; isoangustone A inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; manganese chloride inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; nothofagin inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; nothofagin inhibits the reaction [Glucose results in increased expression of CCL2 protein]; picolinic acid inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; psicose inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; psicose inhibits the reaction [Glucose results in increased expression of CCL2 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Quercetin inhibits the reaction [Glucose results in increased expression of MCP1 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCL2 protein]; Selenium inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; Valsartan inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]
Glucose results in increased expression of CCL2 mRNA; Glucose results in increased expression of CCL2 protein; Glucose results in increased expression of MCP1 mRNA
duanbanhuain A inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; duanbanhuain B inhibits the reaction [Glucose results in increased secretion of CCL2 protein]
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CCL2 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CCL2 mRNA; manganese chloride inhibits the reaction [Glucose results in increased secretion of CCL2 protein]; MIR27B mRNA affects the reaction [Glucose results in increased expression of CCL2 protein]; SNHG1 affects the reaction [Glucose results in increased expression of CCL2 mRNA]; SNHG1 affects the reaction [Glucose results in increased expression of CCL2 protein]; SNHG1 affects the reaction [MIR27B mRNA affects the reaction [Glucose results in increased expression of CCL2 protein]]

PMID:16143069 PMID:16600694 PMID:17178593 PMID:17607302 PMID:17655880 More...

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 28

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CCL28 mRNA

NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997

G

C-C motif chemokine ligand 5

increases expression
multiple interactions
decreases expression

Glucose results in increased expression of CCL5 mRNA
[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of CCL5 mRNA
Glucose results in decreased expression of CCL5 mRNA

PMID:17178593 PMID:31655124 PMID:32613381 PMID:32942007

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 7

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CCL7 mRNA

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

cellular communication network factor 1

increases expression

Glucose results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 2

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased expression of CCN2 protein]; bisindolylmaleimide I inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]; Cadmium inhibits the reaction [Glucose results in increased expression of CCN2 protein]; CCL2 mRNA affects the reaction [Glucose results in increased expression of CCN2 protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCN2 protein]; Zinc inhibits the reaction [Glucose results in increased expression of CCN2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]]; SMARCA4A protein inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]
Aspirin inhibits the reaction [Glucose results in increased expression of CCN2 mRNA]; CCN2 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]; fatostatin inhibits the reaction [Glucose results in increased expression of CCN2 protein]; HIF1A protein affects the reaction [Glucose results in increased expression of CCN2 protein]; MIR217 mRNA affects the reaction [Glucose results in increased expression of CCN2 protein]; Resveratrol inhibits the reaction [Glucose results in increased expression of CCN2 protein]; SIRT1 protein affects the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of CCN2 protein]]
Glucose results in increased expression of CCN2 mRNA; Glucose results in increased expression of CCN2 protein

PMID:10026205 PMID:14586741 PMID:19369054 PMID:21124846 PMID:21367880 More...

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin B1

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

increases expression
multiple interactions

Glucose results in increased expression of CCND1; Glucose results in increased expression of CCND1 mRNA
[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]
resveratrol inhibits the reaction [Glucose results in increased expression of CCND1 protein]
[Glucose co-treated with resveratrol] results in decreased expression of CCND1 mRNA; resveratrol inhibits the reaction [Glucose results in increased expression of CCND1 mRNA]

PMID:23690508 PMID:24064760 PMID:24971582 PMID:27049278 PMID:27481074

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

multiple interactions

[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA; cyclopamine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin E1

increases expression
multiple interactions

Glucose results in increased expression of CCNE1 protein
resveratrol inhibits the reaction [Glucose results in increased expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin L1

increases expression

Glucose results in increased expression of CCNL1 mRNA

NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368

G

C-C motif chemokine receptor 10

multiple interactions
increases expression

fucoxanthin inhibits the reaction [Glucose results in increased expression of CCR10 mRNA]

NCBI chr10:86,108,551...86,110,988
Ensembl chr10:86,108,551...86,110,988

G

C-C motif chemokine receptor 6

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Herbicides] results in decreased expression of CCR6 mRNA

NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603

G

C-C motif chemokine receptor 7

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CCR7 mRNA

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

copper chaperone for superoxide dismutase

multiple interactions

[Glucose co-treated with Lycopene] results in increased expression of CCS mRNA

NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915

G

CD14 molecule

multiple interactions

CD14 protein affects the reaction [Glucose promotes the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; Curcumin inhibits the reaction [Glucose promotes the reaction [Lipopolysaccharides results in increased expression of CD14 protein]]; Glucose promotes the reaction [Lipopolysaccharides results in increased expression of CD14 protein]

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

CD151 molecule (Raph blood group)

multiple interactions

CD151 protein results in decreased susceptibility to [Oxygen deficiency co-treated with Glucose deficiency]

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

CD160 molecule

decreases expression

Glucose results in decreased expression of CD160 mRNA

NCBI chr 2:184,340,820...184,383,421
Ensembl chr 2:184,340,599...184,375,834

G

CD163 molecule

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CD163 mRNA

NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878

G

CD19 molecule

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in decreased expression of CD19 mRNA; [lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CD19 mRNA

NCBI chr 1:180,987,286...180,993,920
Ensembl chr 1:180,987,286...180,993,975

G

CD1d1 molecule

multiple interactions
increases expression

fucoxanthin inhibits the reaction [Glucose results in increased expression of CD1D1 mRNA]

NCBI chr 2:172,423,582...172,427,089
Ensembl chr 2:172,423,582...172,427,089

G

CD226 molecule

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CD226 mRNA

NCBI chr18:82,449,924...82,545,107
Ensembl chr18:82,450,568...82,543,051

G

Cd247 molecule

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CD247 mRNA

NCBI chr13:78,043,302...78,118,437
Ensembl chr13:78,043,307...78,122,263

G

Cd300a molecule

increases expression
multiple interactions

Glucose results in increased expression of CD300A mRNA
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with Glyphosate] results in increased expression of CD300A mRNA

PMID:31525975 PMID:37567420

NCBI chr10:99,929,801...99,942,674
Ensembl chr10:99,929,801...99,942,674

G

CD300 molecule-like family member b

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CD300LB mRNA

NCBI chr10:99,964,801...99,974,790
Ensembl chr10:99,964,801...99,974,790

G

CD36 molecule

multiple interactions
increases expression

(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; [osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA; Fenofibrate inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; lanifibranor inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Pioglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; Rosiglitazone inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]
Glucose results in increased expression of CD36 mRNA

PMID:32613381 PMID:36156098

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

CD3 epsilon subunit of T-cell receptor complex

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of CD3E mRNA

NCBI chr 8:45,303,848...45,315,005
Ensembl chr 8:45,303,852...45,315,022

G

CD40 ligand

multiple interactions

[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose co-treated with 2,4-Dichlorophenoxyacetic Acid] results in increased expression of CD40LG mRNA

NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306

G

CD44 molecule

increases expression
multiple interactions

Glucose results in increased expression of CD44 mRNA
[lard co-treated with Cholesterol, Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of CD44 mRNA

PMID:17178593 PMID:37567420

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G